

Use of Arsenic Trioxide (As₂O₃) in the Treatment of Acute Myeloid Leukemia: Clinical Efficacy and Pharmacokinetics in Relapsed Patients

Blood

89, 3354-3360

DOI: [10.1182/blood.v89.9.3354](https://doi.org/10.1182/blood.v89.9.3354)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. <i>Oncology Reports</i> , 1994, 20, 379.	1.2	10
2	The Tobacco Settlement. <i>New England Journal of Medicine</i> , 1997, 337, 1082-1083.	13.9	9
3	Differentiation Therapy for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 1997, 337, 1076-1077.	13.9	40
4	Emergency Contraception â€” Expanding Opportunities for Primary Prevention. <i>New England Journal of Medicine</i> , 1997, 337, 1078-1079.	13.9	38
5	The Genetics of Dilated Cardiomyopathy â€” Emerging Clues to the Puzzle. <i>New England Journal of Medicine</i> , 1997, 337, 1080-1081.	13.9	58
6	Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines. <i>Blood</i> , 1997, 90, 562-570.	0.6	108
7	Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis. , 1997, 76, 141-149.		72
8	The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. <i>Leukemia</i> , 1998, 12, 1383-1391.	3.3	148
10	Arsenic induces apoptosis in Bâ€‘cell leukaemic cell lines in vitro : activation of caspases and downâ€‘regulation of Bclâ€‘2 protein. <i>British Journal of Haematology</i> , 1998, 102, 1055-1060.	1.2	129
11	Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid. <i>British Journal of Haematology</i> , 1998, 103, 559-562.	1.2	23
12	Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. <i>British Journal of Haematology</i> , 1998, 103, 721-728.	1.2	49
13	Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 1998, 103, 1092-1095.	1.2	120
15	Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RAR α Protein in Acute Promyelocytic Leukemia Cells. <i>Journal of the National Cancer Institute</i> , 1998, 90, 124-133.	3.0	344
16	Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. <i>New England Journal of Medicine</i> , 1998, 339, 1341-1348.	13.9	1,149
17	Arsenic and Apoptosis in the Treatment of Acute Promyelocytic Leukemia. <i>Journal of the National Cancer Institute</i> , 1998, 90, 86-88.	3.0	43
18	Application of Heavy Metal and Cytokine for Differentiation-Inducing Therapy in Acute Promyelocytic Leukemia. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1906-1907.	3.0	16
19	Arsenic â€” New Life for an Old Potion. <i>New England Journal of Medicine</i> , 1998, 339, 1389-1391.	13.9	61
20	Human Herpesvirus 8 â€” Let the Transplantation Physician Beware. <i>New England Journal of Medicine</i> , 1998, 339, 1391-1392.	13.9	11

#	ARTICLE	IF	CITATIONS
21	Pediatric Primary Diffuse Large Cell Lymphoma of Bone With t(3;22)(q27;q11). <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 552-555.	0.3	8
22	Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RAR α Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter α -AIDA Trial. <i>Blood</i> , 1998, 92, 784-789.	0.6	266
23	Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells. <i>Blood</i> , 1998, 91, 4300-4310.	0.6	176
24	Trivalent Antimonials Induce Degradation of the PML-RAR α Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells. <i>Blood</i> , 1998, 92, 4308-4316.	0.6	87
25	Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RAR α Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy. <i>Blood</i> , 1998, 92, 1172-1183.	0.6	123
26	Arsenic Trioxide and Melarsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RAR α Independent Manner. <i>Blood</i> , 1998, 92, 1497-1504.	0.6	212
27	Estimating Total Arsenic Exposure in the United States. , 1999, , 51-60.		9
28	Dithiothreitol Enhances Arsenic Trioxide-Induced Apoptosis in NB4 Cells. <i>Molecular Pharmacology</i> , 1999, 56, 102-109.	1.0	55
29	Malignant Cells Can Be Sensitized to Undergo Growth Inhibition and Apoptosis by Arsenic Trioxide Through Modulation of the Glutathione Redox System. <i>Blood</i> , 1999, 93, 268-277.	0.6	522
30	Phenylarsine Oxide Blocks Interleukin-1 β -Induced Activation of the Nuclear Transcription Factor NF- κ B, Inhibits Proliferation, and Induces Apoptosis of Acute Myelogenous Leukemia Cells. <i>Blood</i> , 1999, 94, 2844-2853.	0.6	72
31	Deconstructing a Disease: RAR α , Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 93, 3167-3215.	0.6	990
32	Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients. <i>Blood</i> , 1999, 94, 3315-3324.	0.6	579
33	Arsenic Trioxide Selectively Induces Acute Promyelocytic Leukemia Cell Apoptosis Via a Hydrogen Peroxide-Dependent Pathway. <i>Blood</i> , 1999, 94, 2102-2111.	0.6	516
34	Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro.. <i>International Journal of Molecular Medicine</i> , 1999, 4, 33-7.	1.8	45
35	A novel retinoic acid-resistant acute promyelocytic leukemia model in vitro and in vivo (review).. <i>International Journal of Molecular Medicine</i> , 1999, 4, 359-64.	1.8	5
36	The Thrombophilic State in Acute Promyelocytic Leukemia. <i>Seminars in Thrombosis and Hemostasis</i> , 1999, 25, 209-215.	1.5	22
37	The molecular biology of acute promyelocytic leukemia. , 1999, 99, 75-124.		39
38	Annexin II and Bleeding in Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 1999, 340, 994-1004.	13.9	379

#	ARTICLE	IF	CITATIONS
39	Re: Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1690-1691.	3.0	20
40	Non-Platinum Antitumor Compounds. , 1999, , 171-199.		10
41	Wild-type and Ras-transformed fibroblasts display differential mitogenic responses to transient sodium arsenite exposure. <i>Toxicological Sciences</i> , 1999, 50, 72-81.	1.4	19
42	Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia. <i>Journal of Experimental Medicine</i> , 1999, 189, 1043-1052.	4.2	303
43	RESPONSE: Re: Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1691-1691.	3.0	2
44	Acute progranulocytic leukaemia: a model for molecular medicine. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 135-150.	1.0	1
45	In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As ₂ O ₃) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family. <i>Tissue Antigens</i> , 1999, 54, 597-602.	1.0	6
46	The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. <i>British Journal of Haematology</i> , 1999, 106, 591-613.	1.2	88
47	Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience. <i>Australian and New Zealand Journal of Medicine</i> , 1999, 29, 385-386.	0.5	8
48	Manganese induces apoptosis of human B cells: caspase-dependent cell death blocked by Bcl-2. <i>Cell Death and Differentiation</i> , 1999, 6, 445-453.	5.0	62
49	In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RAR α protein and the PML retargeting on PML-nuclear bodies. <i>Leukemia</i> , 1999, 13, 739-749.	3.3	37
50	Acute promyelocytic leukemia: from treatment to genetics and back. <i>Oncogene</i> , 1999, 18, 5261-5267.	2.6	25
51	In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. <i>Oncogene</i> , 1999, 18, 5278-5292.	2.6	99
52	Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. <i>British Journal of Cancer</i> , 1999, 81, 796-799.	2.9	114
53	Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. <i>Bone Marrow Transplantation</i> , 1999, 24, 345-348.	1.3	17
54	Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. <i>Annals of Hematology</i> , 1999, 78, 329-332.	0.8	31
55	Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. <i>Medical Oncology</i> , 1999, 16, 58-64.	1.2	84
56	Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. <i>Experimental Hematology</i> , 1999, 27, 845-852.	0.2	69

#	ARTICLE	IF	CITATIONS
57	Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. , 1999, 82, 286-292.		77
58	Medicinal Inorganic Chemistry. <i>Advances in Inorganic Chemistry</i> , 1999, 49, 183-306.	0.4	270
59	Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations. <i>Journal of the National Cancer Institute</i> , 1999, 91, 772-778.	3.0	271
60	Effect of Arsenic Trioxide on Cell Cycle Arrest in Head and Neck Cancer Cell Line PCI-1. <i>Biochemical and Biophysical Research Communications</i> , 1999, 265, 400-404.	1.0	74
61	Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. <i>European Journal of Cancer</i> , 1999, 35, 1258-1263.	1.3	138
63	Tetraploid Acute Promyelocytic Leukemia with Large Bizarre Blast Cell Morphology. <i>Cancer Genetics and Cytogenetics</i> , 1999, 115, 52-55.	1.0	23
64	Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. <i>FEBS Letters</i> , 1999, 455, 59-62.	1.3	157
65	Arsenite Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore. <i>Experimental Cell Research</i> , 1999, 249, 413-421.	1.2	283
66	Editorial. <i>Pathology</i> , 1999, 31, 81-82.	0.3	1
67	Evidence for Early Hematopoietic Progenitor Cell Involvement in Acute Promyelocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 1999, 112, 819-827.	0.4	39
68	PIC-1/SUMO-1-Modified PML-Retinoic Acid Receptor $\hat{\pm}$ Mediates Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia. <i>Molecular and Cellular Biology</i> , 1999, 19, 5170-5178.	1.1	98
69	Extramedullary Disease in Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1999, 33, 219-229.	0.6	75
70	Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>Annals of Internal Medicine</i> , 2000, 133, 881.	2.0	180
71	Recent advances in the treatment of acute leukemia: 1999. <i>Current Opinion in Hematology</i> , 2000, 7, 205-211.	1.2	12
72	Modified intranuclear organization of regulatory factors in human acute leukemias: Reversal after treatment. , 2000, 77, 30-43.		10
73	Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-transretinoic acid. <i>British Journal of Haematology</i> , 2000, 108, 696-702.	1.2	84
74	Arsenic trioxide (As ₂ O ₃)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. <i>Leukemia</i> , 2000, 14, 431-438.	3.3	61
75	Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. <i>Leukemia</i> , 2000, 14, 262-270.	3.3	248

#	ARTICLE	IF	CITATIONS
76	Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. <i>Leukemia</i> , 2000, 14, 343-344.	3.3	28
77	Arsenic trioxide (As ₂ O ₃) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells. <i>Leukemia</i> , 2000, 14, 941-943.	3.3	7
78	Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. <i>Leukemia</i> , 2000, 14, 1006-1013.	3.3	94
79	Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. <i>Leukemia</i> , 2000, 14, 1362-1370.	3.3	145
80	Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 P-glycoprotein-expressing sublines. <i>Leukemia</i> , 2000, 14, 1436-1443.	3.3	135
81	Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. <i>Leukemia</i> , 2000, 14, 1371-1377.	3.3	157
82	Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. <i>Leukemia</i> , 2000, 14, 1743-1750.	3.3	116
83	On-line reversed-phase liquid chromatography hydride generation emission spectrometry: speciation of arsenic in urine of patients intravenously treated with As ₂ O ₃ . <i>Biomedical Applications</i> , 2000, 740, 179-186.	1.7	13
84	New Drugs for the Treatment of Chronic Lymphocytic Leukemia. <i>Reviews in Clinical and Experimental Hematology</i> , 2000, 4, 145-166.	0.1	1
85	Anti-sleeping Sickness Drugs and Cancer Chemotherapy. <i>Parasitology Today</i> , 2000, 16, 7-9.	3.1	56
86	Induction of mitosis-mediated apoptosis by sodium arsenite in HeLa S3 cells. <i>Biochemical Pharmacology</i> , 2000, 60, 771-780.	2.0	37
87	Promising approaches in acute leukemia. , 2000, 18, 57-82.		7
88	Accelerated and blastic phase of chronic myeloid leukemia. <i>Current Treatment Options in Oncology</i> , 2000, 1, 51-62.	1.3	10
89	Differentiating agents in pediatric malignancies: All-trans-retinoic acid and arsenic in acute promyelocytic leukemia. <i>Current Oncology Reports</i> , 2000, 2, 519-523.	1.8	23
90	Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. <i>Blood</i> , 2000, 96, 1525-1530.	0.6	255
91	Successful Treatment of All-Trans Retinoic Acid Resistant and Chemotherapy Naive Acute Promyelocytic Patients with Arsenic Trioxid-e - Two Case Reports. <i>Leukemia and Lymphoma</i> , 2000, 38, 191-194.	0.6	12
92	Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. <i>Journal of Clinical Oncology</i> , 2000, 18, 2620-2625.	0.8	176
93	Minimal Residual Disease in Acute Promyelocytic Leukemia. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 105-117.	0.7	1

#	ARTICLE	IF	CITATIONS
94	Prolonged Third Remission in a Patient With Acute Promyelocytic Leukemia After Consolidation Chemotherapy With Intermittent Intermediate Dose Ara-C and Maintenance With Intermittent all-trans Retinoic Acid (ATRA). <i>Leukemia and Lymphoma</i> , 2000, 36, 625-629.	0.6	1
95	Pathologic, Cytogenetic and Molecular Assessment of Acute Promyelocytic Leukemia Patients Treated with Arsenic Trioxide (As ₂ O ₃). <i>Modern Pathology</i> , 2000, 13, 954-961.	2.9	25
96	Retinoids in chemoprevention and differentiation therapy. <i>Carcinogenesis</i> , 2000, 21, 1271-1279.	1.3	234
97	Arsenic Trioxide Therapy for Relapsed Acute Promyelocytic Leukemia: an Useful Salvage Therapy. <i>Leukemia and Lymphoma</i> , 2000, 38, 283-293.	0.6	37
98	Arsenic-Induced Apoptosis in Malignant Cells <i>In vitro</i> . <i>Leukemia and Lymphoma</i> , 2000, 37, 53-63.	0.6	69
99	Targeted therapies for the myeloid leukaemias. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1197-1205.	1.9	15
100	Retinoic acid (RA) and As ₂ O ₃ treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR α and PLZF-RAR α oncoproteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 10173-10178.	3.3	193
101	Arsenic Trioxide Inhibits Neuroblastoma Growth in Vivo and Promotes Apoptotic Cell Death in Vitro. <i>Biochemical and Biophysical Research Communications</i> , 2000, 277, 179-185.	1.0	60
102	Transcription therapy for acute promyelocytic leukaemia. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 329-346.	1.9	8
103	A new homeopathic approach to neoplastic diseases: from cell destruction to carcinogen-induced apoptosis. <i>The British Homoeopathic Journal</i> , 2000, 89, 78-83.	0.6	13
104	Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. <i>Lancet Oncology</i> , 2000, 1, 101-106.	5.1	71
105	The Effects Of Arsenic Trioxide (As ₂ O ₃) On Human Megakaryocytic Leukemia Cell Lines With a Comparison of its Effects on Other Cell Lineages. <i>Leukemia and Lymphoma</i> , 2000, 38, 153-163.	0.6	34
106	Arsenic Trioxide and the Growth of Human T-cell Leukemia Virus Type I Infected T-cell Lines. <i>Leukemia and Lymphoma</i> , 2000, 37, 649-655.	0.6	28
107	Use of Arsenic Trioxide as an Antivascular and Thermosensitizing Agent in Solid Tumors. <i>Neoplasia</i> , 2000, 2, 555-560.	2.3	53
108	Treatment of acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 153-174.	0.7	71
109	The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 497-529.	0.7	124
110	Endotoxins induce and interferon α ± suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells. <i>FASEB Journal</i> , 2001, 15, 1318-1320.	0.2	18
111	Arsenic Trioxide Induces G2/M Growth Arrest and Apoptosis after Caspase-3 Activation and Bcl-2 Phosphorylation in Promonocytic U937 Cells. <i>Biochemical and Biophysical Research Communications</i> , 2001, 286, 726-734.	1.0	93

#	ARTICLE	IF	CITATIONS
112	Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304. <i>Pharmacological Research</i> , 2001, 44, 513-518.	3.1	53
113	Immunosuppression by arsenic: a comparison of cathepsin L inhibition and apoptosis. <i>International Immunopharmacology</i> , 2001, 1, 647-656.	1.7	30
114	Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. <i>Seminars in Hematology</i> , 2001, 38, 26-36.	1.8	20
115	Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. <i>Seminars in Hematology</i> , 2001, 38, 54-70.	1.8	28
116	Effects of All-Trans-Retinoic Acid and Arsenic Trioxide on the Hemostatic Disturbance Associated with Acute Promyelocytic Leukemia. <i>Thrombosis Research</i> , 2001, 102, 197-204.	0.8	23
117	RETINOID THERAPY OF CHILDHOOD CANCER. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 867-910.	0.9	105
118	Yap1 overproduction restores arsenite resistance to the ABC transporter deficient mutant ycf1 by activating ACR3 expression. <i>Biochemistry and Cell Biology</i> , 2001, 79, 441-448.	0.9	19
119	Alemtuzumab/Arsenic Trioxide/Imatinib Mesylate. <i>Hospital Pharmacy</i> , 2001, 36, 930-935.	0.4	0
120	Erratum for vol. 97, p. 2574. <i>Blood</i> , 2001, 98, 271-271.	0.6	11
121	Acute progranulocytic leukemia. <i>Current Opinion in Oncology</i> , 2001, 13, 8-13.	1.1	10
122	Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. <i>Blood</i> , 2001, 97, 264-269.	0.6	210
123	Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. <i>Blood</i> , 2001, 97, 3931-3940.	0.6	79
124	Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. <i>Blood</i> , 2001, 97, 1514-1516.	0.6	180
125	Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1 and type 2 infected cells by a caspase-3 dependent mechanism involving Bcl-2 cleavage. <i>Blood</i> , 2001, 98, 3762-3769.	0.6	92
126	Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. <i>Blood</i> , 2001, 98, 266-271.	0.6	233
127	Ascorbic acid enhances arsenic trioxide induced cytotoxicity in multiple myeloma cells. <i>Blood</i> , 2001, 98, 805-813.	0.6	252
128	Successful Treatment of a Case of Relapsed Acute Promyelocytic Leukemia with Arsenic Trioxide.. <i>Internal Medicine</i> , 2001, 40, 1136-1139.	0.3	1
129	Arsenic Trioxide Newly Joins Treatment Strategies for Acute Promyelocytic Leukemia. <i>Internal Medicine</i> , 2001, 40, 1165-1165.	0.3	0

#	ARTICLE	IF	CITATIONS
130	United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 3852-3860.	0.8	773
131	Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. <i>Oncologist</i> , 2001, 6, 11-16.	1.9	2
132	The biology of acute promyelocytic leukemia. <i>Current Oncology Reports</i> , 2001, 3, 209-216.	1.8	14
133	Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. <i>British Journal of Haematology</i> , 2001, 113, 257-258.	1.2	10
134	The glycerol channel Fps1p mediates the uptake of arsenite and antimonite in <i>Saccharomyces cerevisiae</i> . <i>Molecular Microbiology</i> , 2001, 40, 1391-1401.	1.2	306
135	Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of P53 and activation of caspase-3. <i>International Journal of Cancer</i> , 2001, 91, 173-179.	2.3	135
136	STUDIES OF APOPTOSIS OF MALIGNANT LYMPHOMA CELLS INDUCED BY ARSENIC TRIOXIDE. <i>Cell Biology International</i> , 2001, 25, 1003-1006.	1.4	12
137	Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca ²⁺ -dependent production of superoxide. <i>International Journal of Cancer</i> , 2001, 92, 518-526.	2.3	116
138	Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study. <i>American Journal of Hematology</i> , 2001, 66, 274-279.	2.0	55
139	Preparation and properties of arsonolipid containing liposomes. <i>Chemistry and Physics of Lipids</i> , 2001, 109, 75-89.	1.5	47
140	Arsenic Trioxide. <i>Medical Oncology</i> , 2001, 18, 239-242.	1.2	30
141	Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. <i>Blood Reviews</i> , 2001, 15, 133-142.	2.8	24
142	Modulation of cell adhesion and viability of cultured murine bone marrow cells by arsenobetaine, a major organic arsenic compound in marine animals. <i>British Journal of Pharmacology</i> , 2001, 132, 143-150.	2.7	17
143	The role of bone marrow transplantation in acute promyelocytic leukemia. <i>Bone Marrow Transplantation</i> , 2001, 28, 219-226.	1.3	37
144	Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. <i>Leukemia</i> , 2001, 15, 735-741.	3.3	145
145	A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. <i>Leukemia</i> , 2001, 15, 1176-1184.	3.3	42
146	Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. <i>Oncogene</i> , 2001, 20, 1-9.	2.6	103
147	Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. <i>Oncogene</i> , 2001, 20, 7161-7177.	2.6	32

#	ARTICLE	IF	CITATIONS
148	Arsenic trioxide, a therapeutic agent for APL. <i>Oncogene</i> , 2001, 20, 7146-7153.	2.6	207
149	Differentiation therapy of human cancer: basic science and clinical applications. , 2001, 90, 105-156.		261
150	Fluorescence in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2001, 131, 125-134.	1.0	30
151	Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As ₂ O ₃) on myeloma cells. <i>Leukemia Research</i> , 2001, 25, 227-235.	0.4	61
152	Co-biomodulation with arsenic trioxide in multiple myeloma. <i>Leukemia Research</i> , 2001, 25, 237-239.	0.4	13
153	Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide11Abbreviations: MRP1, multidrug resistance-associated protein 1; As ₂ O ₃ , arsenic trioxide; MTT, 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; and BSO, buthionine sulfoximine.. <i>Biochemical Pharmacology</i> , 2001, 61, 1387-1391.	2.0	46
154	Arsenic Trioxide for the Treatment of Acute Promyelocytic Leukemia. <i>Cancer Practice</i> , 2001, 9, 155-157.	0.8	8
155	Effects of arsenic trioxide (As ₂ O ₃) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. <i>European Journal of Haematology</i> , 2001, 66, 357-364.	1.1	29
157	Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. <i>Oncologist</i> , 2001, 6, 11-16.	1.9	61
158	Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor ± Oncoprotein Found in Human Acute Promyelocytic Leukemia. <i>Molecular and Cellular Biology</i> , 2001, 21, 7172-7182.	1.1	59
159	Angiogenesis in Lymphoproliferative Disorders. <i>Acta Haematologica</i> , 2001, 106, 184-189.	0.7	20
160	Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells. <i>International Journal of Oncology</i> , 2001, 18, 249.	1.4	13
161	Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies. <i>Leukemia and Lymphoma</i> , 2001, 42, 1265-1273.	0.6	19
162	The Growth Suppressor PML Represses Transcription by Functionally and Physically Interacting with Histone Deacetylases. <i>Molecular and Cellular Biology</i> , 2001, 21, 2259-2268.	1.1	138
163	Risk/Benefit Profile of Arsenic Trioxide. <i>Oncologist</i> , 2001, 6, 29-32.	1.9	45
164	Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrozole, Paclitaxel, Bexarotene. <i>Oncologist</i> , 2001, 6, 4-11.	1.9	86
166	History of the Development of Arsenic Derivatives in Cancer Therapy. <i>Oncologist</i> , 2001, 6, 3-10.	1.9	331
167	Introduction: The History of Arsenic Trioxide in Cancer Therapy. <i>Oncologist</i> , 2001, 6, 1-2.	1.9	334

#	ARTICLE	IF	CITATIONS
168	Arsenic Trioxide Arrests Cells Early in Mitosis Leading to Apoptosis. <i>Cell Cycle</i> , 2002, 1, 200-208.	1.3	27
169	New Therapies in Leukemia: Renewed Hope. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 583-587.	1.8	0
170	Arsenic Trioxide Produces Polymerization of Microtubules and Mitotic Arrest before Apoptosis in Human Tumor Cell Lines. <i>Molecular Pharmacology</i> , 2002, 62, 529-538.	1.0	144
171	UBE1L is a retinoid target that triggers PML/RAR α degradation and apoptosis in acute promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3806-3811.	3.3	117
172	Acquisition of apoptotic resistance in arsenic-induced malignant transformation: role of the JNK signal transduction pathway. <i>Carcinogenesis</i> , 2002, 23, 151-159.	1.3	59
173	CNS Relapses of Acute Promyelocytic Leukemia after All-Trans Retinoic Acid. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1900-1906.	0.9	19
174	Opposite Biological Effects of Arsenic Trioxide and Arsacetin Involve a Different Regulation of Signaling in Human Gastric Cancer MGC-803 Cells. <i>Pharmacology</i> , 2002, 64, 160-168.	0.9	9
175	Advances in the Treatment of Relapsed Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2002, 107, 1-17.	0.7	29
176	Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. <i>International Journal of Oncology</i> , 2002, 21, 603.	1.4	10
177	Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. <i>International Journal of Oncology</i> , 2002, 21, 57.	1.4	49
178	Arsenic Trioxide: Still a Mystery. <i>Cell Cycle</i> , 2002, 1, 183-186.	1.3	8
179	The emergence of resistance to targeted cancer therapeutics. <i>Pharmacogenomics</i> , 2002, 3, 603-623.	0.6	26
180	A Major Human Arsenic Metabolite, Dimethylarsinic Acid, Requires Reduced Glutathione To Induce Apoptosis. <i>Chemical Research in Toxicology</i> , 2002, 15, 629-637.	1.7	55
181	Arsenic Trioxide: Acute Promyelocytic Leukemia and Beyond. <i>Leukemia and Lymphoma</i> , 2002, 43, 1535-1540.	0.6	45
182	Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. <i>Leukemia</i> , 2002, 16, 617-622.	3.3	94
183	Multifaceted Approach to the Treatment of Bcr α -Abl β -Positive Leukemias. <i>Oncologist</i> , 2002, 7, 30-38.	1.9	31
184	Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide. <i>Oncologist</i> , 2002, 7, 1-13.	1.9	26
185	Arsenic trioxide as a novel anticancer agent against human transitional carcinoma characterizing its apoptotic pathway. <i>Anti-Cancer Drugs</i> , 2002, 13, 293-300.	0.7	39

#	ARTICLE	IF	CITATIONS
186	Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. <i>Blood</i> , 2002, 99, 409-426.	0.6	180
187	Acute promyelocytic leukemia: evolving therapeutic strategies. <i>Blood</i> , 2002, 99, 759-767.	0.6	364
188	Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. <i>Blood</i> , 2002, 99, 3136-3143.	0.6	206
189	Prolongation of cardiac repolarization by arsenic trioxide. <i>Blood</i> , 2002, 100, 2249-2252.	0.6	59
190	Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: potentiation by thiamine deficiency. <i>Blood</i> , 2002, 99, 3481-3482.	0.6	40
191	Successful double bone marrow and renal transplantation in a patient with Fanconi anemia. <i>Blood</i> , 2002, 99, 3482-3483.	0.6	11
192	All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood</i> , 2002, 100, 4298-4302.	0.6	427
193	SYNCHROTRON INDUCED X-RAY FLUORESCENCE, APPLIED TO THE STUDY OF A NEW As BASED DRUG AGAINST LEUKAEMIA. <i>Instrumentation Science and Technology</i> , 2002, 20, 565-570.	0.8	6
194	Arsenic Trioxide in Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 12-25.	1.0	37
195	Arsenic Trioxide-Induced Apoptosis and Its Enhancement by Buthionine Sulfoximine in Hepatocellular Carcinoma Cell Lines. <i>Biochemical and Biophysical Research Communications</i> , 2002, 291, 861-867.	1.0	74
196	The significance of minimal residual disease in patients with t(15;17). <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 137-158.	0.7	34
197	Mammalian ABC Transporters in Health and Disease. <i>Annual Review of Biochemistry</i> , 2002, 71, 537-592.	5.0	1,441
198	Targeted removal of PML-RAR \pm protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. <i>Blood</i> , 2002, 100, 1008-1013.	0.6	35
199	The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 281-291.	0.6	32
200	Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 9468-9473.	3.3	46
201	Cytotoxicity of arsenic trioxide to transitional carcinoma cells. <i>Urology</i> , 2002, 60, 346-350.	0.5	26
202	Restoration of p53 tumor suppressor pathway in human cervical carcinoma cells by sodium arsenite. <i>Biochemical and Biophysical Research Communications</i> , 2002, 293, 298-306.	1.0	26
203	Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. <i>Life Sciences</i> , 2002, 70, 2253-2269.	2.0	94

#	ARTICLE	IF	CITATIONS
204	Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: Inhibition of proliferation and induction of apoptosis. <i>Life Sciences</i> , 2002, 71, 275-285.	2.0	47
205	Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. <i>Seminars in Hematology</i> , 2002, 39, 8-13.	1.8	43
206	Expanding the use of arsenic trioxide: Leukemias and beyond. <i>Seminars in Hematology</i> , 2002, 39, 22-26.	1.8	74
207	Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. <i>Drug Resistance Updates</i> , 2002, 5, 162-175.	6.5	41
208	Inhibition by arsenic trioxide of human hepatoma cell growth. <i>Cancer Letters</i> , 2002, 183, 147-153.	3.2	68
209	Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. <i>Cancer Letters</i> , 2002, 181, 11-22.	3.2	37
210	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. <i>Blood</i> , 2002, 99, 1014-1022.	0.6	84
211	Arsenic Trioxide as Effective Therapy for Relapsed Acute Promyelocytic Leukemia. <i>Clinical Journal of Oncology Nursing</i> , 2002, 6, 341-346.	0.3	16
212	Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. <i>Biochemical Pharmacology</i> , 2002, 63, 1831-1842.	2.0	60
213	ADVANCES IN THE UNDERSTANDING AND MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, 6, 60-71.	0.1	15
214	In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. <i>Experimental Hematology</i> , 2002, 30, 729-737.	0.2	93
215	Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. <i>American Journal of Hematology</i> , 2002, 70, 292-299.	2.0	63
216	Abnormalities in hemostasis in acute promyelocytic leukemia. <i>Hematological Oncology</i> , 2002, 20, 33-41.	0.8	60
217	Sodium arsenite suppresses human papillomavirus-16 E6 gene and enhances apoptosis in E6-transfected human lymphoblastoid cells. <i>Journal of Cellular Biochemistry</i> , 2002, 84, 615-624.	1.2	5
218	Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 261-270.	1.5	14
219	Successful Unrelated Bone Marrow Transplantation After Arsenic Trioxide Treatment in a Patient With Relapsed Acute Promyelocytic Leukemia. <i>International Journal of Hematology</i> , 2002, 75, 104-106.	0.7	1
220	Management of acute promyelocytic leukemia. <i>Current Oncology Reports</i> , 2002, 4, 381-389.	1.8	18
221	Dual effects of arsenic trioxide (As ₂ O ₃) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. <i>British Journal of Haematology</i> , 2002, 116, 555-563.	1.2	65

#	ARTICLE	IF	CITATIONS
222	The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 42, 5-24.	2.0	224
223	Antimony and bismuth compounds in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 42, 217-224.	2.0	216
224	Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. <i>British Journal of Haematology</i> , 2002, 117, 130-132.	1.2	46
225	In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 117, 343-350.	1.2	11
227	A metal chelator, diphenylthiocarbazon, induces apoptosis in acute promyelocytic leukemia (APL) cells mediated by a caspase-dependent pathway without a modulation of retinoic acid signaling pathways. <i>Leukemia Research</i> , 2002, 26, 661-668.	0.4	4
228	Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. <i>Leukemia</i> , 2002, 16, 1213-1219.	3.3	97
229	Clinical activity of arsenic trioxide for the treatment of multiple myeloma. <i>Leukemia</i> , 2002, 16, 1835-1837.	3.3	144
230	Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation. <i>Leukemia</i> , 2002, 16, 2455-2456.	3.3	4
231	Retinoic acid resistance in acute promyelocytic leukemia. <i>Leukemia</i> , 2002, 16, 1940-1958.	3.3	136
232	Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 1959-1973.	3.3	178
233	Modelling haematopoietic malignancies in the mouse and therapeutical implications. <i>Oncogene</i> , 2002, 21, 3445-3458.	2.6	45
234	Differentiation induction as a treatment for hematologic malignancies. <i>Oncogene</i> , 2002, 21, 3496-3506.	2.6	25
235	Arsenite Disrupts Mitosis and Induces Apoptosis in SV40-Transformed Human Skin Fibroblasts. <i>Toxicology and Applied Pharmacology</i> , 2002, 180, 83-91.	1.3	50
236	Chronic Arsenic-Exposed Human Prostate Epithelial Cells Exhibit Stable Arsenic Tolerance: Mechanistic Implications of Altered Cellular Glutathione and Glutathione S-transferase. <i>Toxicology and Applied Pharmacology</i> , 2002, 183, 99-107.	1.3	61
237	Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 521-526.	0.8	82
238	Arsonoliposomes, a novel class of arsenic-containing liposomes: effect of palmitoyl-arsonolipid-containing liposomes on the viability of cancer and normal cells in culture. <i>Pharmaceutical Research</i> , 2002, 19, 79-86.	1.7	40
239	The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation. <i>Journal of Bioenergetics and Biomembranes</i> , 2002, 34, 135-145.	1.0	38
240	Arsenic Trioxide and Breast Cancer: Analysis of the Apoptotic, Differentiative and Immunomodulatory Effects. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 61-73.	1.1	78

#	ARTICLE	IF	CITATIONS
241	The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2002, 7, 209-215.	2.2	77
242	Role of JWA in acute promyelocytic leukemia cell differentiation and apoptosis triggered by retinoic acid, 12-tetradecanoylphorbol-13-acetate and arsenic trioxide. <i>Science Bulletin</i> , 2002, 47, 834.	1.7	21
243	Myocardial Toxicity of Arsenic Trioxide in a Mouse Model. <i>Cardiovascular Toxicology</i> , 2002, 2, 63-74.	1.1	44
244	Structural genomics efforts at the Chinese Academy of Sciences and Peking University. <i>Journal of Structural and Functional Genomics</i> , 2003, 4, 137-139.	1.2	10
245	Effect of Ad-p16 combined with CDDP or As ₂ O ₃ on human bladder cancer cells. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2003, 23, 169-172.	1.0	0
246	Treatment of acute promyelocytic Leukemia and other hematologic malignancies with arsenic trioxide: Review of clinical and basic studies. <i>International Journal of Hematology</i> , 2003, 78, 32-39.	0.7	32
247	Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 119-126.	1.1	22
248	Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 47-58.	1.1	41
249	Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2003, 71, 1-8.	1.1	27
250	Nitric oxide production by arsenite. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 533, 173-182.	0.4	46
251	Increasing sensitivity to arsenic trioxide-induced apoptosis by altered telomere state. <i>European Journal of Pharmacology</i> , 2003, 474, 141-147.	1.7	23
252	Direct cardiac effects of As ₂ O ₃ in rabbits: evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration. <i>Toxicology and Applied Pharmacology</i> , 2003, 189, 214-220.	1.3	28
253	Overview of bladder cancer trials in the Cancer and Leukemia Group B. <i>Cancer</i> , 2003, 97, 2090-2098.	2.0	33
254	Use of arsenic trioxide (As ₂ O ₃) in the treatment of patients with acute promyelocytic leukemia. <i>Cancer</i> , 2003, 97, 2218-2224.	2.0	169
255	Electrochemical Biosensor for the Detection of Interaction Between Arsenic Trioxide and DNA Based on Guanine Signal. <i>Electroanalysis</i> , 2003, 15, 613-619.	1.5	102
256	Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide. <i>Cell Biology International</i> , 2003, 27, 953-958.	1.4	13
257	Organic phenyl arsonic acid compounds with potent antileukemic activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 581-583.	1.0	19
258	An exploratory investigation of the effect of arsenic trioxide on anti-Gal antibody production in baboons. <i>Xenotransplantation</i> , 2003, 10, 80-87.	1.6	4

#	ARTICLE	IF	CITATIONS
259	Novel therapies for multiple myeloma. <i>British Journal of Haematology</i> , 2003, 120, 10-17.	1.2	61
260	Antitumor effect of arsenic trioxide in murine xenograft model. <i>Cancer Science</i> , 2003, 94, 1010-1014.	1.7	36
261	Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. <i>Leukemia</i> , 2003, 17, 931-940.	3.3	151
262	Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. <i>Leukemia</i> , 2003, 17, 1211-1262.	3.3	91
263	Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. <i>Leukemia</i> , 2003, 17, 1333-1337.	3.3	69
264	Opportunities for Trisenox [®] (arsenic trioxide) in the treatment of myelodysplastic syndromes. <i>Leukemia</i> , 2003, 17, 1499-1507.	3.3	111
265	Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. <i>Leukemia</i> , 2003, 17, 1454-1463.	3.3	146
266	Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. <i>Leukemia</i> , 2003, 17, 2189-2195.	3.3	35
267	Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1 α . <i>Leukemia</i> , 2003, 17, 2065-2073.	3.3	99
268	The Molecular Mechanism of Arsenic Trioxide-Induced Apoptosis and Oncosis in Leukemia/Lymphoma Cell Lines. <i>Acta Haematologica</i> , 2003, 110, 1-10.	0.7	31
269	The importance of molecular monitoring in acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 503-520.	0.7	27
270	Treatment of older adults with acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 495-501.	0.7	15
271	Blockage of Multidrug Resistance-Associated Proteins Potentiates the Inhibitory Effects of Arsenic Trioxide on CYP1A1 Induction by Polycyclic Aromatic Hydrocarbons. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 145-155.	1.3	39
272	Metal Complexes as Drugs and Chemotherapeutic Agents. , 2003, , 809-840.		60
273	Acute and chronic arsenic toxicity. <i>Postgraduate Medical Journal</i> , 2003, 79, 391-396.	0.9	848
274	Arsenic Trioxide (Trisenox [®]) Therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem Cell Transplantation. <i>Oncologist</i> , 2003, 8, 132-140.	1.9	54
275	Inhibition of Mitochondrial Respiration. <i>Journal of Biological Chemistry</i> , 2003, 278, 37832-37839.	1.6	438
276	Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 2326-2334.	0.8	146

#	ARTICLE	IF	CITATIONS
277	Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis. <i>Journal of Clinical Oncology</i> , 2003, 21, 4239-4247.	0.8	76
278	Arsenic Stimulates Angiogenesis and Tumorigenesis In Vivo. <i>Toxicological Sciences</i> , 2003, 76, 271-279.	1.4	103
279	Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies. <i>Journal of Clinical Oncology</i> , 2003, 21, 3609-3615.	0.8	212
280	Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells. <i>Experimental and Molecular Medicine</i> , 2003, 35, 83-90.	3.2	29
281	Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. <i>International Journal of Hyperthermia</i> , 2003, 19, 575-589.	1.1	35
282	Ham-Wasserman Lecture. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 1-13.	0.9	40
283	Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. <i>International Journal of Oncology</i> , 2003, 22, 1271.	1.4	5
284	Reactive oxygen species and antioxidants in apoptosis of esophageal cancer cells induced by As ₂ O ₃ . <i>International Journal of Molecular Medicine</i> , 2003, 11, 479.	1.8	7
285	Tetraarsenic oxide induces apoptosis in U937 leukemic cells through a reactive oxygen species-dependent pathway. <i>International Journal of Oncology</i> , 2003, 23, 943.	1.4	2
286	Arsenic Trioxide Induces Apoptosis in Pancreatic Cancer Cells via Changes in Cell Cycle, Caspase Activation, and GADD Expression. <i>Pancreas</i> , 2003, 27, 174-179.	0.5	54
287	Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. <i>Current Opinion in Hematology</i> , 2003, 10, 31-39.	1.2	16
288	Inhibition of NF- κ B essentially contributes to arsenic-induced apoptosis. <i>Blood</i> , 2003, 102, 1028-1034.	0.6	149
289	Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. <i>Blood</i> , 2003, 101, 4098-4104.	0.6	284
290	Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. <i>Blood</i> , 2003, 101, 4990-4997.	0.6	78
291	Understanding Novel Therapeutic Agents for Multiple Myeloma. <i>Clinical Journal of Oncology Nursing</i> , 2003, 7, 521-528.	0.3	10
292	Trials of Arsenic Trioxide in Multiple Myeloma. <i>Cancer Control</i> , 2003, 10, 370-374.	0.7	38
293	Treatment of Relapsed Acute Promyelocytic Leukemia. <i>Oncology Research and Treatment</i> , 2003, 26, 373-379.	0.8	6
294	Acute Myeloid Leukemia: A Classification and Treatment Update. <i>Clinical Journal of Oncology Nursing</i> , 2003, 7, 535-540.	0.3	11

#	ARTICLE	IF	CITATIONS
295	Molecular mechanisms of chemoprevention and therapy of cancer by retinoids. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2663.	3.0	10
296	Therapy of Acute Promyelocytic Leukemia. <i>Advances in Pharmacology</i> , 2004, 51, 35-58.	1.2	4
297	Arsenates in the Treatment of Hematological Malignancies. <i>Cancer Reviews: Asia-Pacific</i> , 2004, 02, 161-171.	0.1	0
298	Myelodysplastic syndromes. <i>The Hematology Journal</i> , 2004, 5, 1-8.	2.0	49
299	Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents. <i>Circulation</i> , 2004, 109, 26-29.	1.6	98
300	RWJ-241947 (MCC-555), A Unique Peroxisome Proliferator-Activated Receptor- β Ligand with Antitumor Activity against Human Prostate Cancer in Vitro and in Beige/Nude/ X-Linked Immunodeficient Mice and Enhancement of Apoptosis in Myeloma Cells Induced by Arsenic Trioxide. <i>Clinical Cancer Research</i> , 2004, 10, 1508-1520.	3.2	29
301	Pathogenesis, Diagnosis and Monitoring of Residual Disease in Acute Promyelocytic Leukaemia. <i>Acta Haematologica</i> , 2004, 112, 55-67.	0.7	41
302	Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. <i>Leukemia and Lymphoma</i> , 2004, 45, 2387-2401.	0.6	42
303	All-trans retinoic acid/As ₂ O ₃ combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5328-5335.	3.3	564
304	Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4578-4583.	3.3	207
305	Biography of Zhu Chen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5325-5327.	3.3	0
306	Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells. <i>Carcinogenesis</i> , 2004, 26, 53-63.	1.3	51
307	Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species. <i>Current Pharmaceutical Design</i> , 2004, 10, 841-853.	0.9	10
308	Relevance of Pathologic Classifications and Diagnosis of Acute Myeloid Leukemia to Clinical Trials and Clinical Practice. , 2004, 121, 45-67.		15
309	Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells. <i>Journal of Endocrinology</i> , 2004, 182, 325-337.	1.2	38
310	Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1). <i>Journal of Biological Chemistry</i> , 2004, 279, 32700-32708.	1.6	227
311	Mechanisms of Arsenic-Induced Prolongation of Cardiac Repolarization. <i>Molecular Pharmacology</i> , 2004, 66, 33-44.	1.0	277
312	Phenylarsine Oxide (PAO) More Intensely Induces Apoptosis in Acute Promyelocytic Leukemia and As ₂ O ₃ -Resistant APL Cell Lines than As ₂ O ₃ by Activating the Mitochondrial Pathway. <i>Leukemia and Lymphoma</i> , 2004, 45, 987-995.	0.6	18

#	ARTICLE	IF	CITATIONS
313	Arsenite Sensitizes Human Melanomas to Apoptosis via Tumor Necrosis Factor α -mediated Pathway. <i>Journal of Biological Chemistry</i> , 2004, 279, 22747-22758.	1.6	56
314	Cardiac monitoring of patients receiving arsenic trioxide therapy. <i>British Journal of Haematology</i> , 2004, 124, 610-617.	1.2	46
315	The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. <i>Cell Research</i> , 2004, 14, 81-85.	5.7	54
316	Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. <i>Leukemia</i> , 2004, 18, 1258-1269.	3.3	19
317	Arsenic trioxide: expanding roles for an ancient drug?. <i>Leukemia</i> , 2004, 18, 1457-1459.	3.3	21
318	A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. <i>Leukemia</i> , 2004, 18, 1518-1521.	3.3	75
319	Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. <i>Oncogene</i> , 2004, 23, 1239-1247.	2.6	176
320	Dual effects of glutathione-S-transferase γ on As ₂ O ₃ action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. <i>Oncogene</i> , 2004, 23, 3945-3952.	2.6	37
321	Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. <i>British Journal of Pharmacology</i> , 2004, 142, 749-755.	2.7	46
322	Role of glutathione in dimethylarsinic acid-induced apoptosis. <i>Toxicology and Applied Pharmacology</i> , 2004, 198, 354-365.	1.3	20
323	Cellular glutathione prevents cytolethality of monomethylarsonic acid. <i>Toxicology and Applied Pharmacology</i> , 2004, 195, 129-141.	1.3	26
324	Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. <i>Cancer Cell</i> , 2004, 5, 389-401.	7.7	132
325	Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. <i>European Journal of Haematology</i> , 2004, 72, 166-171.	1.1	37
326	Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. <i>European Journal of Haematology</i> , 2004, 72, 280-284.	1.1	18
327	Role of oxidative damage in the genotoxicity of arsenic. <i>Free Radical Biology and Medicine</i> , 2004, 37, 574-581.	1.3	146
328	Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease. <i>International Journal of Hematology</i> , 2004, 79, 420-433.	0.7	41
329	Molecular mechanisms of arsenic carcinogenesis. <i>Molecular and Cellular Biochemistry</i> , 2004, 255, 57-66.	1.4	237
330	Effects of arsenic trioxide on human renal cell carcinoma lines in vitro. <i>Chinese Journal of Integrative Medicine</i> , 2004, 10, 48-51.	0.7	1

#	ARTICLE	IF	CITATIONS
331	Inhibition of bovine herpesvirus-4 replication by arsenite through downregulation of the extracellular signal-regulated kinase signaling pathway. <i>Journal of Biomedical Science</i> , 2004, 11, 500-510.	2.6	3
332	Zinc protects against arsenic-induced apoptosis in a neuronal cell line, measured by DEVD-caspase activity. <i>BioMetals</i> , 2004, 17, 707-713.	1.8	31
333	Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide. <i>Annals of Hematology</i> , 2004, 83, 751-758.	0.8	52
334	The therapy of relapsed acute leukaemia in adults. <i>Blood Reviews</i> , 2004, 18, 39-63.	2.8	13
335	Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF- κ B activation. <i>International Journal of Cancer</i> , 2004, 112, 596-606.	2.3	46
336	Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. <i>International Journal of Cancer</i> , 2004, 112, 707-712.	2.3	71
337	Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As ₂ O ₃) on human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2004, 93, 173-187.	1.2	92
338	Simultaneously multi-parameter determination of hematonosis cell apoptosis by two-photon and confocal laser scanning microscopy. <i>Journal of Clinical Laboratory Analysis</i> , 2004, 18, 271-275.	0.9	3
339	Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 197-203.	0.4	40
340	Equilibrium characterization of the As(III)-cysteine and the As(III)-glutathione systems in aqueous solution. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1151-1159.	1.5	123
341	Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. <i>Leukemia Research</i> , 2004, 28, 909-919.	0.4	60
342	Alteration in the cellular response to retinoic acid of a human acute promyelocytic leukemia cell line, UF-1, carrying a patient-derived mutant PML-RAR α chimeric gene. <i>Leukemia Research</i> , 2004, 28, 959-967.	0.4	2
343	The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. <i>Leukemia Research</i> , 2004, 28, 891-900.	0.4	161
344	Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature. <i>Leukemia Research</i> , 2004, 28, 1347-1350.	0.4	13
345	Oral arsenic trioxide poisoning and secondary hazard from gastric content. <i>Annals of Emergency Medicine</i> , 2004, 44, 625-627.	0.3	13
346	Arsenic trioxide in the treatment of haematological malignancies. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 589-597.	1.0	24
347	The PML-RAR α Fusion Protein and Targeted Therapy for Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 639-648.	0.6	39
348	Arsenic Trioxide Liposomes: Encapsulation Efficiency and In Vitro Stability. <i>Journal of Liposome Research</i> , 2004, 14, 27-38.	1.5	40

#	ARTICLE	IF	CITATIONS
350	Signalling Pathways Activated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells. <i>Leukemia and Lymphoma</i> , 2004, 45, 2175-2185.	0.6	26
351	Integrating phenotypic and expression profiles to map arsenic-response networks. <i>Genome Biology</i> , 2004, 5, R95.	13.9	167
352	ROS stress in cancer cells and therapeutic implications. <i>Drug Resistance Updates</i> , 2004, 7, 97-110.	6.5	1,686
353	Evaluation of immunotoxic and immunodisruptive effects of inorganic arsenite on human monocytes/macrophages. <i>International Immunopharmacology</i> , 2004, 4, 1661-1673.	1.7	6
354	Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. <i>Cell Death and Differentiation</i> , 2004, 11, 737-746.	5.0	164
355	Acute promyelocytic leukemia as a paradigm for targeted therapy. <i>Seminars in Hematology</i> , 2004, 41, 27-32.	1.8	43
356	Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide. <i>Anti-Cancer Drugs</i> , 2004, 15, 779-785.	0.7	24
357	In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl ⁺ positive cell lines. <i>Blood</i> , 2004, 103, 208-215.	0.6	93
358	JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. <i>Blood</i> , 2004, 103, 3496-3502.	0.6	142
359	Combined effects of As ₄ S ₄ and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. <i>Blood</i> , 2004, 104, 4219-4225.	0.6	73
361	Reverse Effects of Tetraarsenic Oxide on the Angiogenesis Induced by Nerve Growth Factor in the Rat Cornea. <i>Journal of Veterinary Medical Science</i> , 2004, 66, 1091-1095.	0.3	11
362	33As Metallotherapeutic Arsenic Compounds. , 2005, , 297-311.		1
363	Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. <i>Current Opinion in Hematology</i> , 2005, 12, 1-6.	1.2	74
365	Acute promyelocytic leukemia: A model of molecular target based therapy. <i>Hematology</i> , 2005, 10, 270-280.	0.7	19
366	Arsenic in cancer therapy. <i>Anti-Cancer Drugs</i> , 2005, 16, 119-127.	0.7	65
367	Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. <i>Blood</i> , 2005, 105, 1237-1245.	0.6	66
368	Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. <i>Blood</i> , 2005, 106, 304-310.	0.6	74
369	Cytolethality of Glutathione Conjugates with Monomethylarsenic or Dimethylarsenic Compounds. <i>Biological and Pharmaceutical Bulletin</i> , 2005, 28, 1827-1832.	0.6	16

#	ARTICLE	IF	CITATIONS
370	Arsenic Trioxide in the Treatment of Relapsed and Refractory Acute Promyelocytic Leukemia. <i>Internal Medicine</i> , 2005, 44, 775-776.	0.3	6
371	Delayed Recovery of Normal Hematopoiesis in Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia: A Comparison to All-trans Retinoic Acid Treatment. <i>Internal Medicine</i> , 2005, 44, 818-824.	0.3	9
372	Myelodysplastic syndromes: A comprehensive review. <i>Blood Reviews</i> , 2005, 19, 301-319.	2.8	68
373	On-line coupling of microdialysis sampling with high performance liquid chromatography and hydride generation atomic absorption spectrometry for continuous in vivo monitoring of arsenic species in the blood of living rabbits. <i>Analytica Chimica Acta</i> , 2005, 543, 38-45.	2.6	24
374	A new method for radiochemical separation of arsenic from irradiated germanium oxide. <i>Applied Radiation and Isotopes</i> , 2005, 63, 343-351.	0.7	46
375	Treatment concepts of acute promyelocytic leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 261-274.	2.0	83
376	Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies. <i>International Journal of Hematology</i> , 2005, 82, 224-229.	0.7	99
377	Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 872-877.	1.2	28
378	Involvement of mitochondrial aggregation in arsenic trioxide (As ₂ O ₃)-induced apoptosis in human glioblastoma cells. <i>Cancer Science</i> , 2005, 96, 825-833.	1.7	87
379	Triterpenoid CDDO-Im downregulates PML/RAR α expression in acute promyelocytic leukemia cells. <i>Cell Death and Differentiation</i> , 2005, 12, 523-531.	5.0	21
380	Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. <i>Leukemia</i> , 2005, 19, 234-244.	3.3	50
381	Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. <i>Oncogene</i> , 2005, 24, 980-991.	2.6	377
382	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κ B. <i>Oncogene</i> , 2005, 24, 390-398.	2.6	61
383	Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. <i>Oncogene</i> , 2005, 24, 1904-1913.	2.6	69
384	Arsenic trioxide (As ₂ O ₃) induces apoptosis through activation of Bax in hematopoietic cells. <i>Oncogene</i> , 2005, 24, 3339-3347.	2.6	61
385	Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. <i>Oncogene</i> , 2005, 24, 7031-7042.	2.6	32
386	MRP-1 expression levels determine strain-specific susceptibility to sodium arsenic-induced renal injury between C57BL/6 and BALB/c mice. <i>Toxicology and Applied Pharmacology</i> , 2005, 203, 53-61.	1.3	34
387	Inorganic arsenite alters macrophage generation from human peripheral blood monocytes. <i>Toxicology and Applied Pharmacology</i> , 2005, 203, 145-153.	1.3	24

#	ARTICLE	IF	CITATIONS
388	Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. <i>Toxicology and Applied Pharmacology</i> , 2005, 204, 216-237.	1.3	1,222
389	Preventive mechanism of cellular glutathione in monomethylarsonic acid-induced cytolethality. <i>Toxicology and Applied Pharmacology</i> , 2005, 206, 54-65.	1.3	27
390	Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. <i>Gynecologic Oncology</i> , 2005, 99, 726-729.	0.6	24
391	Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 120-130.	1.2	32
392	Arsenic trioxide represses constitutive activation of NF- κ B and COX-2 expression in human acute myeloid leukemia, HL-60. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 695-707.	1.2	45
393	Arsenic trioxide (As ₂ O ₃) inhibits invasion of HT1080 human fibrosarcoma cells: Role of nuclear factor- κ B and reactive oxygen species. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 955-969.	1.2	42
394	Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 170-178.	1.1	23
395	New agents in the treatment of childhood leukemias and myelodysplastic syndromes. <i>Current Oncology Reports</i> , 2005, 7, 399-405.	1.8	5
397	Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 2396-2410.	0.8	231
398	Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia. <i>PLoS Medicine</i> , 2005, 2, e12.	3.9	45
399	Science Star over Asia. <i>PLoS Biology</i> , 2005, 3, e322.	2.6	4
400	Butylhydroquinone Protects Cells Genetically Deficient in Glutathione Biosynthesis from Arsenite-Induced Apoptosis Without Significantly Changing Their Prooxidant Status. <i>Toxicological Sciences</i> , 2005, 87, 365-384.	1.4	50
401	Heme-regulated Inhibitor Kinase-mediated Phosphorylation of Eukaryotic Translation Initiation Factor 2 Inhibits Translation, Induces Stress Granule Formation, and Mediates Survival upon Arsenite Exposure. <i>Journal of Biological Chemistry</i> , 2005, 280, 16925-16933.	1.6	362
402	Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-Trans-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 120-126.	0.8	122
403	Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1128-1135.	1.9	13
404	In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon- α . <i>Leukemia and Lymphoma</i> , 2005, 46, 347-355.	0.6	27
405	Use of arsenic trioxide in hematological malignancies: insight into the clinical development of a novel agent. <i>Current Medical Research and Opinion</i> , 2005, 21, 403-411.	0.9	44
406	Baicalin, a component of <i>Scutellaria radix</i> from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. <i>Blood</i> , 2005, 105, 3312-3318.	0.6	157

#	ARTICLE	IF	CITATIONS
407	As ₂ O ₃ enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein. <i>Journal of Drug Targeting</i> , 2005, 13, 235-243.	2.1	3
408	Mutant FLT3 signaling contributes to a block in myeloid differentiation. <i>Leukemia and Lymphoma</i> , 2005, 46, 1679-1687.	0.6	34
409	Vitamin C protects HL60 and U266 cells from arsenic toxicity. <i>Blood</i> , 2005, 105, 4004-4012.	0.6	56
410	Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. <i>Current Cancer Therapy Reviews</i> , 2005, 1, 239-250.	0.2	0
411	PRAM-1 Potentiates Arsenic Trioxide-induced JNK Activation. <i>Journal of Biological Chemistry</i> , 2005, 280, 9043-9048.	1.6	8
412	Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. <i>International Journal of Oncology</i> , 2005, 27, 537.	1.4	7
413	Bax and Bak are required for cytochrome c release during arsenic trioxide-induced apoptosis. <i>Cancer Biology and Therapy</i> , 2005, 4, 465-473.	1.5	65
414	Biological effects of ATRA and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts. <i>Leukemia and Lymphoma</i> , 2005, 46, 257-263.	0.6	1
415	Overview of drug therapy for multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2005, 11, 83-100.	0.5	14
416	Acute Arsenic Poisoning in Two Siblings. <i>Pediatrics</i> , 2005, 116, 249-257.	1.0	30
417	Myelodysplastic Syndrome. <i>Annual Review of Medicine</i> , 2005, 56, 1-16.	5.0	109
418	Inhibition of Eukaryotic Translation Initiation by the Marine Natural Product Pateamine A. <i>Molecular Cell</i> , 2005, 20, 709-722.	4.5	220
419	High Expression of <i>bcl-x_L</i> in K562 Cells and Its Role in the Low Sensitivity of K562 to Realgar-Induced Apoptosis. <i>Acta Haematologica</i> , 2005, 113, 247-254.	0.7	6
421	Lipid Encapsulation of Arsenic Trioxide Attenuates Cytotoxicity and Allows for Controlled Anticancer Drug Release. <i>Journal of the American Chemical Society</i> , 2006, 128, 13348-13349.	6.6	105
422	Arsenic Trioxide. <i>American Journal of Cancer</i> , 2006, 5, 183-191.	0.4	8
423	Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?. <i>Leukemia and Lymphoma</i> , 2006, 47, 2282-2287.	0.6	18
424	Mechanisms of Apoptosis Induction and Cell Cycle Regulation in Irradiated Leukemia U937 Cells and Enhancement by Arsenic Trioxide. <i>Radiation Research</i> , 2006, 165, 390-399.	0.7	7
425	Interferon- β Plays Protective Roles in Sodium Arsenite-Induced Renal Injury by Up-Regulating Intrarenal Multidrug Resistance-Associated Protein 1 Expression. <i>American Journal of Pathology</i> , 2006, 169, 1118-1128.	1.9	55

#	ARTICLE	IF	CITATIONS
426	Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. <i>Experimental Cell Research</i> , 2006, 312, 4120-4138.	1.2	31
427	Highlights from: The 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA; June 2-6, 2006. <i>Clinical Leukemia</i> , 2006, 1, 9-12.	0.2	0
428	Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. <i>Leukemia and Lymphoma</i> , 2006, 47, 1629-1638.	0.6	32
429	Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 192-198.	1.4	50
430	Medicinal Properties of Organometallic Compounds. , 0, , 177-210.		31
431	Arsenite induces apoptosis in hepatocytes through an enhancement of the activation of Jun N-terminal kinase and p38 mitogen-activated protein kinase caused by partial hepatectomy. <i>Toxicology Letters</i> , 2006, 165, 257-264.	0.4	26
432	Rice (<i>Oryza sativa</i> L.) inhibits growth and induces differentiation of human leukemic U937 cells through activation of peripheral blood mononuclear cells. <i>Food and Chemical Toxicology</i> , 2006, 44, 1724-1729.	1.8	31
433	In vitro dual effect of arsenic trioxide on hemopoiesis: Inhibition of erythropoiesis and stimulation of megakaryocytic maturation. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 59-76.	0.6	9
434	Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2006, 236, 250-258.	3.2	27
435	Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. <i>Human Pathology</i> , 2006, 37, 298-311.	1.1	126
436	Evaluation of immunotoxic and immunodisruptive effects of inorganic arsenite on human monocytes/macrophages. <i>International Immunopharmacology</i> , 2006, 6, 304-315.	1.7	39
437	Relapsed acute myeloid leukemia. , 2006, , 540-547.		0
438	Acute myeloid leukemia. , 2006, , 499-539.		2
439	Clinical Pharmacokinetic Study of Arsenic Trioxide in an Acute Promyelocytic Leukemia (APL) Patient: Speciation of Arsenic Metabolites in Serum and Urine. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 1022-1027.	0.6	53
440	Effect of 2-Methoxyestradiol, Buthionine Sulfoximine and Hydrogen Peroxide on the Viability of Renal Carcinoma Cell Lines (ACHN and ACVB). <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 1064-1067.	0.6	2
441	Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. <i>Blood</i> , 2006, 108, 103-106.	0.6	66
442	Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. <i>Blood</i> , 2006, 107, 4880-4887.	0.6	39
443	Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. <i>Blood</i> , 2006, 107, 2627-2632.	0.6	313

#	ARTICLE	IF	CITATIONS
444	Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies. <i>Current Pharmaceutical Design</i> , 2006, 12, 111-128.	0.9	19
445	Arrhythmogenic Effects of Arsenic Trioxide in Patients With Acute Promyelocytic Leukemia and an Electrophysiological Study in Isolated Guinea Pig Papillary Muscles. <i>Circulation Journal</i> , 2006, 70, 1407-1414.	0.7	28
446	Standard and experimental therapy in cutaneous T-cell lymphomas. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 52-57.	0.7	15
447	Arsenic-Induced Cell Death in Liver and Brain of Experimental Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 38-43.	1.2	104
448	Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. <i>Cancer Science</i> , 2006, 97, 540-545.	1.7	36
449	Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215). <i>British Journal of Pharmacology</i> , 2006, 149, 888-897.	2.7	36
450	Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. <i>Leukemia</i> , 2006, 20, 1009-1016.	3.3	43
451	Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 493-498.	0.4	27
452	Two Cases of Acute Promyelocytic Leukemia Complicated by Torsade de Pointes during Arsenic Trioxide Therapy. <i>International Journal of Hematology</i> , 2006, 83, 318-323.	0.7	38
453	Recurrent Extramedullary Relapse of Acute Promyelocytic Leukemia after Allogeneic Stem Cell Transplantation: Successful Treatment by Arsenic Trioxide in Combination with Local Radiotherapy. <i>International Journal of Hematology</i> , 2006, 83, 337-340.	0.7	18
454	Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 221-228.	2.0	7
455	Role of GSTP1-1 in mediating the effect of As ₂ O ₃ in the Acute Promyelocytic Leukemia cell line NB4. <i>Annals of Hematology</i> , 2006, 85, 681-687.	0.8	23
456	Arsenic is decreased in target organs during viral infection in mice. <i>Journal of Trace Elements in Medicine and Biology</i> , 2006, 20, 121-126.	1.5	7
457	JWA, a novel signaling molecule, involved in all-trans retinoic acid induced differentiation of HL-60 cells. <i>Journal of Biomedical Science</i> , 2006, 13, 357-371.	2.6	20
458	Sensitivity of leukemic cell line HL-60 to combination of neferine and arsenic. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2006, 18, 183-187.	0.7	0
459	Arsenic trioxide as a treatment for myelodysplastic syndrome. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 34-38.	1.2	4
460	Effects of exogenous cysteine on inorganic and organic arsenicals-induced cytolethality. <i>Applied Organometallic Chemistry</i> , 2006, 20, 549-556.	1.7	0
461	Determination of degradation compounds derived from Lewisite by high performance liquid chromatography/inductively coupled plasma-mass spectrometry. <i>Applied Organometallic Chemistry</i> , 2006, 20, 591-596.	1.7	18

#	ARTICLE	IF	CITATIONS
462	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , 2006, 106, 2624-2629.	2.0	33
463	Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF- κ B activation in Ewing sarcoma cells. <i>International Journal of Cancer</i> , 2006, 119, 1723-1727.	2.3	22
464	Improved Tumor Destruction with Arsenic Trioxide and Radiofrequency Ablation in Three Animal Models. <i>Radiology</i> , 2006, 240, 82-89.	3.6	47
465	Depletion of Securin Increases Arsenite-Induced Chromosome Instability and Apoptosis via a p53-Independent Pathway. <i>Toxicological Sciences</i> , 2006, 90, 73-86.	1.4	19
466	Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle. <i>Current Pharmaceutical Design</i> , 2006, 12, 73-91.	0.9	24
467	Real-time PCR analysis of PML-RAR α in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. <i>Annals of Oncology</i> , 2006, 17, 1553-1559.	0.6	18
468	Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. <i>Annals of Oncology</i> , 2006, 17, 131-134.	0.6	178
469	Arsenic Trioxide Induces Apoptosis of Human Monocytes during Macrophagic Differentiation through Nuclear Factor- κ B-Related Survival Pathway Down-Regulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 304-314.	1.3	68
470	Chronic Exposure to Methylated Arsenicals Stimulates Arsenic Excretion Pathways and Induces Arsenic Tolerance in Rat Liver Cells. <i>Toxicological Sciences</i> , 2006, 91, 70-81.	1.4	33
471	Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation. <i>Clinical Cancer Research</i> , 2006, 12, 6817-6825.	3.2	42
472	Antimony-Based Antileishmanial Compounds Prolong the Cardiac Action Potential by an Increase in Cardiac Calcium Currents. <i>Molecular Pharmacology</i> , 2006, 69, 1216-1225.	1.0	42
473	Induction of Centrosome Amplification during Arsenite-Induced Mitotic Arrest in CGL-2 Cells. <i>Cancer Research</i> , 2006, 66, 2098-2106.	0.4	53
474	Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. <i>Leukemia and Lymphoma</i> , 2006, 47, 1062-1068.	0.6	57
475	The Emerging Role of Arsenic Trioxide as an Immunomodulatory Agent in the Management of Multiple Myeloma. <i>Acta Haematologica</i> , 2006, 116, 1-7.	0.7	16
476	Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 81-88.	0.6	47
477	Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promyelocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo. <i>Leukemia and Lymphoma</i> , 2006, 47, 521-529.	0.6	17
478	Eukaryotic Initiation Factor 2 α -independent Pathway of Stress Granule Induction by the Natural Product Pateamine A. <i>Journal of Biological Chemistry</i> , 2006, 281, 32870-32878.	1.6	229
479	Activation of the Mitogen- and Stress-activated Kinase 1 by Arsenic Trioxide. <i>Journal of Biological Chemistry</i> , 2006, 281, 22446-22452.	1.6	55

#	ARTICLE	IF	CITATIONS
480	Human Macrophages Constitute Targets for Immunotoxic Inorganic Arsenic. <i>Journal of Immunology</i> , 2006, 177, 3019-3027.	0.4	119
481	Transcription Factor Profiling Shows New Ways Towards New Treatment Options of Cutaneous T cell lymphomas. <i>Current Drug Discovery Technologies</i> , 2007, 4, 24-30.	0.6	17
482	Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells. <i>Haematologica</i> , 2007, 92, 838-841.	1.7	19
483	Telomere attrition, and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-cell leukemia cell line molt-4 cells. <i>Cancer Biology and Therapy</i> , 2007, 6, 1197-1203.	1.5	14
485	ATF4-Dependent Oxidative Induction of the DNA Repair Enzyme Ape1 Counteracts Arsenite Cytotoxicity and Suppresses Arsenite-Mediated Mutagenesis. <i>Molecular and Cellular Biology</i> , 2007, 27, 8834-8847.	1.1	46
486	Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2007, 362, 959-971.	1.8	126
487	Arsenite Slows S Phase Progression via Inhibition of cdc25A Dual Specificity Phosphatase Gene Transcription. <i>Toxicological Sciences</i> , 2007, 99, 70-78.	1.4	20
488	Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2240-2248.	1.9	27
489	Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13438-13443.	3.3	66
490	Treatment of Acute Promyelocytic Leukemia by Retinoids. , 2007, 313, 101-128.		56
491	Synergism between Arsenic Trioxide and Heat Shock Protein 90 Inhibitors on Signal Transducer and Activator of Transcription Protein 3 Activityâ€”Pharmacodynamic Drug-Drug Interaction Modeling. <i>Clinical Cancer Research</i> , 2007, 13, 2261-2270.	3.2	19
492	Lysosomes and Trivalent Arsenic Treatment in Acute Promyelocytic Leukemia. <i>Journal of the National Cancer Institute</i> , 2007, 99, 41-52.	3.0	27
493	Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. <i>Haematologica</i> , 2007, 92, 753-762.	1.7	47
495	Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR α -positive leukemic stem cells. <i>Haematologica</i> , 2007, 92, 323-331.	1.7	81
496	2. All-trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. <i>Internal Medicine</i> , 2007, 46, 91-94.	0.3	22
497	Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. <i>Blood</i> , 2007, 109, 740-746.	0.6	122
498	A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR α transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. <i>Blood</i> , 2007, 110, 59-66.	0.6	158
499	Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. <i>Blood</i> , 2007, 110, 2084-2091.	0.6	53

#	ARTICLE	IF	CITATIONS
500	Therapeutic potential of arsenic trioxide with or without interferon- α for relapsed/refractory adult T-cell leukemia/lymphoma. <i>Haematologica</i> , 2007, 92, 719-720.	1.7	21
501	Targeting Transcription Factors in Acute Leukemia in Children. <i>Current Drug Targets</i> , 2007, 8, 727-737.	1.0	18
502	Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia: A Comprehensive Review. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 997-1004.	2.0	14
503	Arsenical-based cancer drugs. <i>Cancer Treatment Reviews</i> , 2007, 33, 542-564.	3.4	339
504	The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis. <i>Cancer Letters</i> , 2007, 256, 238-245.	3.2	9
505	From traditional Chinese medicine to rational cancer therapy. <i>Trends in Molecular Medicine</i> , 2007, 13, 353-361.	3.5	470
508	Acute Myelogenous Leukemia. , 2007, , .		0
509	Mutant Transcription Factors and Tyrosine Kinases as Therapeutic Targets for Leukemias: From Acute Promyelocytic Leukemia to Chronic Myeloid Leukemia and Beyond. <i>Advances in Cancer Research</i> , 2007, 98, 191-220.	1.9	6
510	New Data with Arsenic Trioxide in Leukemias and Myelodysplastic Syndromes. <i>Clinical Lymphoma and Myeloma</i> , 2007, 8, S7-S12.	1.4	12
512	Current treatment of acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 289-291.	1.7	16
514	Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. <i>Leukemia Research</i> , 2007, 31, 329-339.	0.4	183
515	Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. <i>Leukemia Research</i> , 2007, 31, 301-313.	0.4	9
516	Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. <i>Leukemia Research</i> , 2007, 31, 1585-1587.	0.4	42
517	Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax. <i>Oncogene</i> , 2007, 26, 6150-6159.	2.6	15
518	Tim18, a component of the mitochondrial translocator, mediates yeast cell death induced by arsenic. <i>Biochemistry (Moscow)</i> , 2007, 72, 843-847.	0.7	8
519	Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF- κ B and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. <i>Cell Death and Differentiation</i> , 2007, 14, 306-317.	5.0	109
520	Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase C β . <i>Leukemia</i> , 2007, 21, 1488-1495.	3.3	43
521	Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. <i>Leukemia</i> , 2007, 21, 2117-2127.	3.3	23

#	ARTICLE	IF	CITATIONS
522	Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. <i>Cell Research</i> , 2007, 17, 274-276.	5.7	48
523	P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2008, 140, 169-180.	1.2	43
524	Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of α -synuclein. <i>Journal of Pineal Research</i> , 2007, 43, 163-171.	3.4	75
525	Leukemia, an effective model for chemical biology and target therapy. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 1316-1324.	2.8	13
526	From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 1434-1449.	2.8	9
527	JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. <i>Cellular Signalling</i> , 2007, 19, 1315-1327.	1.7	62
528	Bioaccessibility and excretion of arsenic in Niu Huang Jie Du Pian pills. <i>Toxicology and Applied Pharmacology</i> , 2007, 222, 357-364.	1.3	79
529	Endoplasmic reticulum stress is involved in arsenite-induced oxidative injury in rat brain. <i>Toxicology and Applied Pharmacology</i> , 2007, 224, 138-146.	1.3	39
530	Preparation and in vitro Studies of Stealth PEGylated PLGA Nanoparticles as Carriers for Arsenic Trioxide. <i>Chinese Journal of Chemical Engineering</i> , 2007, 15, 795-801.	1.7	15
531	N-Acetylcysteine Attenuates Arsenite-Induced Oxidative Injury in Dorsal Root Ganglion Explants. <i>Annals of the New York Academy of Sciences</i> , 2007, 1122, 276-288.	1.8	21
532	Establishment of an Arsenic Trioxide-Resistant Human Leukemia Cell Line That Shows Multidrug Resistance. <i>International Journal of Hematology</i> , 2007, 85, 26-31.	0.7	13
533	Arsenic metabolism in multiple myeloma and astrocytoma cells. <i>Biological Trace Element Research</i> , 2007, 116, 5-28.	1.9	12
534	Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 485-493.	1.1	64
535	Arsenic trioxide and neuroblastoma cytotoxicity. <i>Journal of Bioenergetics and Biomembranes</i> , 2007, 39, 35-41.	1.0	21
536	PML-RAR α inhibitors (ATRA, tamibaroten, arsenic trioxide) for acute promyelocytic leukemia. <i>International Journal of Clinical Oncology</i> , 2007, 12, 313-317.	1.0	44
537	ACUTE LEUKEMIAS XII. <i>Annals of Hematology</i> , 2008, 87, 21-98.	0.8	1
538	Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 727-737.	1.1	20
539	Studies on the mechanism of arsenic trioxide-induced apoptosis in HepG2 human hepatocellular carcinoma cells. <i>Chinese Journal of Clinical Oncology</i> , 2008, 5, 22-25.	0.0	4

#	ARTICLE	IF	CITATIONS
540	QT Prolongation: A Case of Arsenical Pericardial and Pleural Effusion. <i>Cardiovascular Toxicology</i> , 2008, 8, 41-44.	1.1	12
541	Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. <i>International Journal of Hematology</i> , 2008, 87, 210-216.	0.7	22
542	Traitement des leucémies aiguës promyélocyaires de l'adulte. <i>Oncologie</i> , 2008, 10, 290-294.	0.2	1
543	Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: A single center experience. <i>Pediatric Blood and Cancer</i> , 2008, 51, 210-215.	0.8	24
544	Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. <i>Cancer</i> , 2008, 112, 1131-1138.	2.0	22
545	Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 2059-2070.	1.2	22
546	Syntheses of 1-thio- α -D-xylitol and α -D-ribose esters of diorganoarsinous acids and their anticancer activity. <i>Heteroatom Chemistry</i> , 2008, 19, 199-206.	0.4	16
547	Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60 cells. <i>Leukemia Research</i> , 2008, 32, 327-333.	0.4	15
548	Photochemical reaction of dimethylarsinous iodide in aerated methanol: A contribution to arsenic radical chemistry. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2008, 195, 175-182.	2.0	5
549	Realgar-induced differentiation is associated with MAPK pathways in HL60 cells. <i>Cell Biology International</i> , 2008, 32, 1497-1505.	1.4	27
550	Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 123-134.	2.8	62
551	Arsenic trioxide: safety issues and their management. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 296-304.	2.8	50
552	A novel arsenical has antitumor activity toward As ₂ O ₃ -resistant and MRP1/ABCC1-overexpressing cell lines. <i>Leukemia</i> , 2008, 22, 1853-1863.	3.3	52
553	Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia. <i>Leukemia</i> , 2008, 22, 1125-1130.	3.3	5
554	PML targeting eradicates quiescent leukaemia-initiating cells. <i>Nature</i> , 2008, 453, 1072-1078.	13.7	517
555	Resveratrol protects against arsenic trioxide-induced cardiotoxicity <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 2008, 154, 105-113.	2.7	108
556	Arsenite-induced cytotoxicity in dorsal root ganglion explants. <i>Free Radical Biology and Medicine</i> , 2008, 44, 1553-1561.	1.3	16
557	Heterocyclic organobismuth(III) induces apoptosis of human promyelocytic leukemic cells through activation of caspases and mitochondrial perturbation. <i>Biochemical Pharmacology</i> , 2008, 76, 974-986.	2.0	46

#	ARTICLE	IF	CITATIONS
558	Formation of dimethylthioarsenicals in red blood cells. <i>Toxicology and Applied Pharmacology</i> , 2008, 227, 390-399.	1.3	68
559	Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest. <i>Toxicology and Applied Pharmacology</i> , 2008, 229, 252-261.	1.3	36
560	Arsenic trioxide in environmentally and clinically relevant concentrations interacts with calcium homeostasis and induces cell type specific cell death in tumor and non-tumor cells. <i>Toxicology Letters</i> , 2008, 179, 34-42.	0.4	39
561	A Comprehensive Review of Acute Promyelocytic Leukemia in Children. <i>Acta Haematologica</i> , 2008, 119, 73-82.	0.7	23
562	Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. <i>Annals of Oncology</i> , 2008, 19, 1927-1934.	0.6	51
563	Acute promyelocytic leukemia: from highly fatal to highly curable. <i>Blood</i> , 2008, 111, 2505-2515.	0.6	1,107
564	Targeted Cancer Therapy. , 2008, , .		11
565	N-(Î ² -Elemene-13-yl)tryptophan methyl ester induces apoptosis in human leukemia cells and synergizes with arsenic trioxide through a hydrogen peroxide dependent pathway. <i>Cancer Letters</i> , 2008, 269, 165-173.	3.2	35
566	Glutathione-dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2. <i>Environmental Toxicology and Pharmacology</i> , 2008, 26, 102-108.	2.0	21
567	Resistance against novel anticancer metal compounds: Differences and similarities. <i>Drug Resistance Updates</i> , 2008, 11, 1-16.	6.5	201
568	Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death. <i>Cell Research</i> , 2008, 18, 458-471.	5.7	42
569	Arsenic Trioxide and Acute Promyelocytic Leukemia: A Drug for All Stages of Disease. <i>Clinical Leukemia</i> , 2008, 2, 107-112.	0.2	1
570	Arsenic trioxide. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1773-1785.	0.9	44
571	Antitumor Effects of Arsenic Trioxide in Transformed Human Thyroid Cells. <i>Thyroid</i> , 2008, 18, 1183-1193.	2.4	14
572	Treatment Strategies in Myelodysplastic Syndromes. <i>Cancer Investigation</i> , 2008, 26, 208-216.	0.6	13
573	Identification of the Major Arsenic-Binding Protein in Rat Plasma As the Ternary Dimethylarsinousâˆ™Hemoglobinâˆ™Haptoglobin Complex. <i>Chemical Research in Toxicology</i> , 2008, 21, 678-685.	1.7	23
574	KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 4593-4602.	3.2	39
575	Mineral Arsenicals in Traditional Medicines: Orpiment, Realgar, and Arsenolite. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 363-368.	1.3	189

#	ARTICLE	IF	CITATIONS
576	Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 941-946.	0.5	10
577	Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2060-2069.	1.9	42
578	An International Pilot Study of Oncology Physicians' Opinions and Practices on Complementary and Alternative Medicine (CAM). <i>Integrative Cancer Therapies</i> , 2008, 7, 70-75.	0.8	35
579	Herbogenomics: From Traditional Chinese Medicine to Novel Therapeutics. <i>Experimental Biology and Medicine</i> , 2008, 233, 1059-1065.	1.1	47
580	Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses. <i>Journal of Biological Chemistry</i> , 2008, 283, 1992-2001.	1.6	40
581	Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2. <i>Journal of Biological Chemistry</i> , 2008, 283, 12034-12042.	1.6	35
582	Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. <i>Annals of Oncology</i> , 2008, 19, 1488-1494.	0.6	23
583	Integrative Medicine: The Experience from China. <i>Journal of Alternative and Complementary Medicine</i> , 2008, 14, 3-7.	2.1	79
584	Catalase activity and arsenic sensitivity in acute leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1976-1981.	0.6	22
585	Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. <i>Blood</i> , 2008, 111, 566-573.	0.6	113
586	BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. <i>Blood</i> , 2008, 111, 5152-5162.	0.6	72
587	Transcriptome and Proteome Analyses of Drug Interactions with Natural Products. <i>Current Drug Metabolism</i> , 2008, 9, 1038-1048.	0.7	18
588	Induction of NKG2D Ligands and Subsequent Enhancement of NK Cell-mediated Lysis of Cancer Cells by Arsenic Trioxide. <i>Journal of Immunotherapy</i> , 2008, 31, 475-486.	1.2	30
589	Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 553-556.	0.6	41
590	Arsenic-Based Antineoplastic Drugs and Their Mechanisms of Action. <i>Metal-Based Drugs</i> , 2008, 2008, 1-13.	3.8	62
591	Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF- κ B in HCT116 colon cancer cells. <i>Oncology Reports</i> , 0, , .	1.2	4
593	Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin. <i>Inflammation and Allergy: Drug Targets</i> , 2009, 8, 21-27.	1.8	11
594	The Enhancement of Drug Sensitivity of Human AFP-Producing Gastric Carcinoma Cell Line FU97 to Arsenic Trioxide Using AFP as Targeting siRNA. , 2009, , .		0

#	ARTICLE	IF	CITATIONS
595	Long-term efficacy and safety of <i>all-trans</i> retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3342-3347.	3.3	380
596	Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15956-15960.	3.3	86
597	Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. American Journal of Health-System Pharmacy, 2009, 66, 1913-1918.	0.5	35
598	Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia. Toxicology and Industrial Health, 2009, 25, 505-515.	0.6	30
599	Use of All- <i>trans</i> Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in Patients with Newly Diagnosed Acute Promyelocytic Leukemia and for Consolidation/Maintenance in CR Patients. Acta Haematologica, 2009, 121, 1-8.	0.7	47
600	Arsenic Trioxide in a Hemodialytic Patient with Acute Promyelocytic Leukemia. Acta Haematologica, 2009, 122, 52-53.	0.7	14
601	New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas. Skin Pharmacology and Physiology, 2009, 22, 322-334.	1.1	22
602	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology, 2009, 27, 504-510.	0.8	355
603	Therapy-induced <i>PML/RARA</i> Proteolysis and Acute Promyelocytic Leukemia Cure. Clinical Cancer Research, 2009, 15, 6321-6326.	3.2	91
604	Arsenic Trioxide Inhibits Hepatitis C Virus RNA Replication through Modulation of the Glutathione Redox System and Oxidative Stress. Journal of Virology, 2009, 83, 2338-2348.	1.5	33
605	Three Epigenetic Drugs Up-Regulate Homeobox Gene <i>Rhox5</i> in Cancer Cells through Overlapping and Distinct Molecular Mechanisms. Molecular Pharmacology, 2009, 76, 1072-1081.	1.0	35
606	Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Molecular Cancer Therapeutics, 2009, 8, 160-170.	1.9	36
607	Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy, 2009, 5, 472-483.	4.3	91
608	Metabolic profiling studies on the toxicological effects of realgar in rats by 1H NMR spectroscopy. Toxicology and Applied Pharmacology, 2009, 234, 314-325.	1.3	136
609	Treatment of Acute Promyelocytic Leukemia During Pregnancy. Pharmacotherapy, 2009, 29, 709-724.	1.2	44
610	Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia. Archives of Drug Information, 2009, 2, 59-65.	1.6	24
611	Combination treatment with arsenic trioxide and irradiation enhances apoptotic effects in U937 cells through increased mitotic arrest and ROS generation. Chemico-Biological Interactions, 2009, 179, 304-313.	1.7	23
612	Arsenic in Human History and Modern Societies. , 0, , 277-302.		3

#	ARTICLE	IF	CITATIONS
613	Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. <i>Hematological Oncology</i> , 2009, 27, 11-16.	0.8	35
614	Effect of bovine colostrum on the growth inhibition and differentiation of human leukemic U937 cells. <i>Journal of the Science of Food and Agriculture</i> , 2009, 89, 965-969.	1.7	4
615	Arsenic trioxide enhances the therapeutic efficacy of adjuvant post-operative chemotherapy of gastric carcinoma while protecting bone marrow. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 406-410.	0.1	0
616	Arsenic induces telomerase expression and maintains telomere length in human cord blood cells. <i>Toxicology</i> , 2009, 260, 132-141.	2.0	50
617	Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. <i>Molecular and Cellular Biochemistry</i> , 2009, 331, 207-214.	1.4	24
618	Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells. <i>Science Bulletin</i> , 2009, 54, 4094-4101.	1.7	2
619	Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 689-697.	1.9	61
620	Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 780-790.	3.3	20
621	Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system. <i>Annals of Hematology</i> , 2009, 88, 1047-1058.	0.8	20
622	Va€PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenicâ€induced toxicity. <i>Cancer Science</i> , 2009, 100, 382-388.	1.7	11
623	Arsenic trioxide suppresses paclitaxelâ€induced mitotic arrest. <i>Cell Proliferation</i> , 2009, 42, 404-411.	2.4	11
624	Stemming out of a new PML era?. <i>Cell Death and Differentiation</i> , 2009, 16, 1083-1092.	5.0	19
625	Transcriptional changes associated with reduced spontaneous liver tumor incidence in mice chronically exposed to high dose arsenic. <i>Toxicology</i> , 2009, 266, 6-15.	2.0	13
626	Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes. <i>Journal of Trace Elements in Medicine and Biology</i> , 2009, 23, 61-68.	1.5	41
627	When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). <i>Leukemia Research</i> , 2009, 33, 1178-1182.	0.4	14
628	Arsenic(III) Species Inhibit Oxidative Protein Folding <i>in Vitro</i>. <i>Biochemistry</i> , 2009, 48, 424-432.	1.2	82
629	Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2009, 35, 32-46.	3.4	801
630	Arsenite medicinal use, metabolism, pharmacokinetics and monitoring in human hair. <i>Biochimie</i> , 2009, 91, 1260-1267.	1.3	39

#	ARTICLE	IF	CITATIONS
631	Tetra-arsenic oxide (Tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect. <i>Cancer Letters</i> , 2009, 277, 212-217.	3.2	9
632	Oral co-administration of α -lipoic acid, quercetin and captopril prevents gallium arsenide toxicity in rats. <i>Environmental Toxicology and Pharmacology</i> , 2009, 28, 140-146.	2.0	48
633	A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. <i>Current Opinion in Genetics and Development</i> , 2009, 19, 51-59.	1.5	47
634	Hypoxia-HIF-1 α -C/EBP β /Runx1 signaling in leukemic cell differentiation. <i>Pathophysiology</i> , 2009, 16, 297-303.	1.0	19
635	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2009, 113, 1875-1891.	0.6	856
636	Efficacy of Transarterial Embolization with Arsenic Trioxide Oil Emulsion in a Rabbit VX2 Liver Tumor Model. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1365-1370.	0.2	12
637	Heterocyclic Organobismuth(III) Compound Targets Tubulin to Induce G2/M Arrest in HeLa Cells. <i>Journal of Pharmacological Sciences</i> , 2009, 109, 573-582.	1.1	23
638	A Novel Combination Therapy With Arsenic Trioxide and Parthenolide Against Pancreatic Cancer Cells. <i>Pancreas</i> , 2009, 38, e114-e123.	0.5	37
639	Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. <i>Blood</i> , 2009, 114, 5512-5521.	0.6	98
640	The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. <i>Oncology Reports</i> , 2009, 22, .	1.2	13
641	Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: Long-term follow-up of patients treated at S. Martino Hospital, Genoa. <i>Oncology Reports</i> , 2009, 21, 1045-52.	1.2	1
642	Reactive Oxygen Species, Cancer and Anti-Cancer Therapies. <i>Current Chemical Biology</i> , 2009, 3, 342-366.	0.2	138
643	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i> , 2010, 116, 3751-3757.	0.6	348
644	Andrographolide inhibits growth of acute promyelocytic leukaemia cells by inducing retinoic acid receptor-independent cell differentiation and apoptosis. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 69-78.	1.2	34
645	Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1295-1301.	1.2	6
646	Molecular mechanisms of leukemia-associated protein degradation. <i>Frontiers of Medicine in China</i> , 2010, 4, 363-370.	0.1	3
647	Arsenic Trioxide Inhibits Cholangiocarcinoma Cell Growth and induces Apoptosis. <i>Pathology and Oncology Research</i> , 2010, 16, 413-420.	0.9	6
648	Speciation of arsenic in urine following intravenous administration of arsthinol in mice. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2010, 35, 59-65.	0.6	2

#	ARTICLE	IF	CITATIONS
649	Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF- κ B-mediated induction of XIAP, cIAP2, BCL-XL and survivin. <i>Medical Oncology</i> , 2010, 27, 833-842.	1.2	38
650	Relapsed APL patient with variant NPM-RAR α fusion responded to arsenic trioxide-based therapy and achieved long-term survival. <i>International Journal of Hematology</i> , 2010, 91, 708-710.	0.7	14
651	Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. <i>Chinese Journal of Integrative Medicine</i> , 2010, 16, 368-377.	0.7	23
652	Leukemia stem cells. <i>Seminars in Cancer Biology</i> , 2010, 20, 71-76.	4.3	65
653	Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells. <i>Journal of Hematology and Oncology</i> , 2010, 3, 28.	6.9	82
654	Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 110-120.	1.0	21
655	Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. <i>Chemico-Biological Interactions</i> , 2010, 183, 222-230.	1.7	16
656	Distribution and speciation of arsenic after intravenous administration of monomethylmonothioarsonic acid in rats. <i>Chemosphere</i> , 2010, 81, 206-213.	4.2	20
657	Arsenite down-regulates cytochrome P450 1A1 at the transcriptional and posttranslational levels in human HepG2 cells. <i>Free Radical Biology and Medicine</i> , 2010, 48, 1399-1409.	1.3	25
658	Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. <i>Experimental Cell Research</i> , 2010, 316, 2174-2188.	1.2	77
661	Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. <i>Leukemia Research</i> , 2010, 34, 85-92.	0.4	49
662	Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome. <i>Leukemia Research</i> , 2010, 34, e25-e26.	0.4	5
663	Gefitinib enhances arsenic trioxide (AS ₂ O ₃)-induced differentiation of acute promyelocytic leukemia cell line. <i>Leukemia Research</i> , 2010, 34, 1501-1505.	0.4	22
664	Arsenic trioxide – An old drug rediscovered. <i>Blood Reviews</i> , 2010, 24, 191-199.	2.8	244
665	Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. <i>Cancer Science</i> , 2010, 101, 948-954.	1.7	70
666	Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 151, 209-220.	1.2	44
667	Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival. <i>International Journal of Laboratory Hematology</i> , 2010, 32, 230-238.	0.7	21
668	Arsenite induces oxidative injury in rat brain. <i>Annals of the New York Academy of Sciences</i> , 2010, 1199, 27-35.	1.8	11

#	ARTICLE	IF	CITATIONS
669	Arsenic trioxide-induced apoptosis of chronic lymphocytic leukemia cells. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e77-85.	0.7	12
670	PML-RAR α ; enhances autophagic activity through inhibiting Akt/mTOR pathway. <i>Nature Precedings</i> , 2010, .	0.1	0
671	Candidate Single Nucleotide Polymorphism Markers for Arsenic Responsiveness of Protein Targets. <i>Bioinformatics and Biology Insights</i> , 2010, 4, BBI.S5498.	1.0	10
672	Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data. <i>Journal of Clinical Oncology</i> , 2010, 28, 3866-3871.	0.8	235
673	Arsenic trioxide associated toothache. <i>Journal of Oncology Pharmacy Practice</i> , 2010, 16, 127-128.	0.5	6
674	Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13432-13437.	3.3	277
675	Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1047-1053.	0.8	88
676	Harnessing traditional Chinese medicine to improve cancer therapy: issues for future development. <i>Therapeutic Delivery</i> , 2010, 1, 335-344.	1.2	7
677	Opinion: Why traditional knowledge is important in drug discovery. <i>Future Medicinal Chemistry</i> , 2010, 2, 1405-1409.	1.1	9
680	Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C β -protein kinase C-p38 MAPK cascade. <i>Translational Research</i> , 2010, 155, 97-108.	2.2	6
681	Utilization of Molecular Phenotypes to Detect Relapse and Optimize the Management of Acute Promyelocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S139-S143.	0.2	0
682	Quantitative Proteomic Analysis Reveals the Perturbation of Multiple Cellular Pathways in HL-60 Cells Induced by Arsenite Treatment. <i>Journal of Proteome Research</i> , 2010, 9, 1129-1137.	1.8	33
683	Arsenic Trioxide Controls the Fate of the PML-RAR α Oncoprotein by Directly Binding PML. <i>Science</i> , 2010, 328, 240-243.	6.0	690
684	Coarse-Grained Molecular Dynamics Study of Permeability Enhancement in DPPC Bilayers by Incorporation of Lysolipid. <i>Journal of Physical Chemistry B</i> , 2010, 114, 5053-5060.	1.2	27
685	As ₂ O ₃ may be a treatment option for adenoid cystic carcinoma of salivary gland. <i>Medical Hypotheses</i> , 2010, 75, 490-491.	0.8	3
686	Arsenic trioxide induces endoplasmic reticulum stress-related events in neutrophils. <i>International Immunopharmacology</i> , 2010, 10, 508-512.	1.7	30
687	Cytoprotective effects of silymarin on epithelial cells against arsenic-induced apoptosis in contrast with quercetin cytotoxicity. <i>Life Sciences</i> , 2010, 87, 309-315.	2.0	19
688	Small mitochondria-targeting molecules as anti-cancer agents. <i>Molecular Aspects of Medicine</i> , 2010, 31, 75-92.	2.7	119

#	ARTICLE	IF	CITATIONS
689	Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. <i>Cancer Letters</i> , 2010, 292, 64-72.	3.2	63
690	Humic acid enhances the cytotoxic effects of arsenic trioxide on human cervical cancer cells. <i>Environmental Toxicology and Pharmacology</i> , 2010, 29, 117-125.	2.0	13
691	The Absence of Interleukin-6 Enhanced Arsenite-Induced Renal Injury by Promoting Autophagy of Tubular Epithelial Cells with Aberrant Extracellular Signal-Regulated Kinase Activation. <i>American Journal of Pathology</i> , 2010, 176, 40-50.	1.9	39
693	Acute promyelocytic leukemia: what are the treatment options?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 587-596.	0.9	16
694	Biological extraction of realgar by <i>Acidithiobacillus ferrooxidans</i> and its <i>in vitro</i> and <i>in vivo</i> antitumor activities. <i>Pharmaceutical Biology</i> , 2010, 48, 40-47.	1.3	16
695	Poisonous Contacts. <i>Science</i> , 2010, 328, 184-185.	6.0	8
696	Arsenic trioxide cooperates with all-trans-retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML ^{RAR} ± negative human myeloblastic leukemia cells. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-14.	0.6	43
697	Development and modeling of arsenic-trioxide-loaded thermosensitive liposomes for anticancer drug delivery. <i>Journal of Liposome Research</i> , 2011, 21, 106-115.	1.5	22
698	Arsenic trioxide in acute promyelocytic leukemia: potion not poison. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1317-1319.	1.1	25
699	A study on the thermochemotherapy effect of nanosized As ₂ O ₃ /MZF thermosensitive magnetoliposomes on experimental hepatoma <i>in vitro</i> and <i>in vivo</i> . <i>Nanotechnology</i> , 2011, 22, 315102.	1.3	22
700	The Application of Delivery Systems for DNA Methyltransferase Inhibitors. <i>BioDrugs</i> , 2011, 25, 227-242.	2.2	12
701	An Evidence-based Perspective of Arsenic Trioxide (As ₂ O ₃) for Cancer Patients. <i>Evidence-based Anticancer Complementary and Alternative Medicine</i> , 2011, , 37-64.	0.1	1
702	Buckwheat Polysaccharide Exerts Antiproliferative Effects in THP-1 Human Leukemia Cells by Inducing Differentiation. <i>Journal of Medicinal Food</i> , 2011, 14, 26-33.	0.8	22
703	S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagy. <i>International Journal of Molecular Medicine</i> , 2012, 29, 65-72.	1.8	28
704	Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 1215-1233.	0.9	17
705	Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2753-2757.	0.8	190
706	Cellular Effects of Heavy Metals. , 2011, , .		60
707	Herbal therapy use by cancer patients: A literature review on case reports. <i>European Journal of Cancer</i> , 2011, 47, 508-514.	1.3	133

#	ARTICLE	IF	CITATIONS
708	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. Antioxidants and Redox Signaling, 2011, 15, 1085-1127.	2.5	420
709	The medicinal use of realgar (As ₄ S ₄) and its recent development as an anticancer agent. Journal of Ethnopharmacology, 2011, 135, 595-602.	2.0	93
710	Sulindac and its metabolites: Sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines. Toxicology in Vitro, 2011, 25, 1075-1084.	1.1	5
711	The down-regulation of galectin-1 expression is a specific biomarker of arsenic toxicity. Toxicology Letters, 2011, 205, 38-46.	0.4	5
712	Antiproliferative and anti-invasive effects of inorganic and organic arsenic compounds on human and murine melanoma cells <i>in vitro</i> . Journal of Pharmacy and Pharmacology, 2011, 63, 1202-1210.	1.2	5
714	YY1 Is a Novel Potential Therapeutic Target for the Treatment of HPV Infection-Induced Cervical Cancer by Arsenic Trioxide. International Journal of Gynecological Cancer, 2011, 21, 1097-1104.	1.2	27
715	Arsenic " Pesticides with an Ambivalent Character. , 2011, , .		0
716	The Molecular Mechanism for Differentiation Therapy of Malignant Glioma. , 0, , .		1
717	Molecular and Cellular Mechanism Studies on Anticancer Effects of Chinese Medicines. , 2011, , .		0
718	Studying arsenic trioxide-induced apoptosis of Colo-16 cells with two-photon and confocal laser scanning microscopy. African Journal of Biotechnology, 2011, 10, 13019-13027.	0.3	5
719	Comprehensively Surveying Structure and Function of RING Domains from Drosophila melanogaster. PLoS ONE, 2011, 6, e23863.	1.1	11
720	Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism. Current Drug Metabolism, 2011, 12, 287-299.	0.7	12
721	From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117, 6425-6437.	0.6	170
722	Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood, 2011, 118, 1600-1609.	0.6	105
723	Free LIF receptor β -chain distal cytoplasmic motifs enhance Jak2-independent STAT3 phosphorylation and induce differentiation in HL-60 cells. Oncology Reports, 2011, 26, 399-404.	1.2	6
725	Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 280-317.	2.3	56
726	Advances in therapies for acute promyelocytic leukemia. Cancer Science, 2011, 102, 1929-1937.	1.7	39
727	Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicology and Applied Pharmacology, 2011, 257, 198-208.	1.3	40

#	ARTICLE	IF	CITATIONS
728	The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis. <i>Leukemia Research</i> , 2011, 35, 1170-1177.	0.4	27
729	Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. <i>Free Radical Biology and Medicine</i> , 2011, 51, 2195-2209.	1.3	18
730	Lipoic acid ameliorates arsenic trioxide-induced HO-1 expression and oxidative stress in THP-1 monocytes and macrophages. <i>Chemico-Biological Interactions</i> , 2011, 190, 129-138.	1.7	23
731	Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1. <i>Chemico-Biological Interactions</i> , 2011, 193, 88-96.	1.7	4
732	Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. <i>Chemico-Biological Interactions</i> , 2011, 193, 162-171.	1.7	38
733	Current treatment strategy of acute promyelocytic leukemia. <i>Frontiers of Medicine</i> , 2011, 5, 341-347.	1.5	18
734	Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. <i>Journal of Neuro-Oncology</i> , 2011, 104, 449-458.	1.4	31
735	Arsenite-Induced Apoptosis Is Prevented by Selenite in A375 Cell Line. <i>Biological Trace Element Research</i> , 2011, 140, 7-17.	1.9	7
736	miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. <i>Medical Oncology</i> , 2011, 28, 211-218.	1.2	45
737	Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. <i>International Journal of Hematology</i> , 2011, 93, 199-205.	0.7	19
738	MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. <i>Tumor Biology</i> , 2011, 32, 179-188.	0.8	73
739	Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction. <i>Frontiers of Medicine</i> , 2011, 5, 45-52.	1.5	3
740	Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. <i>Molecular Cancer</i> , 2011, 10, 142.	7.9	101
741	Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 762-768.	2.0	54
742	Authentication of the 31 species of toxic and potent chinese materia medica by microscopic technique assisted by ICP-MS analysis, part 4: Four kinds of toxic and potent mineral arsenical CMMs. <i>Microscopy Research and Technique</i> , 2011, 74, 1-8.	1.2	13
743	Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged ≤ 60 years with acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 4831-4868.	2.0	16
744	Arsenic trioxide-induced apoptosis in TM4 Sertoli cells: The potential involvement of p21 expression and p53 phosphorylation. <i>Toxicology</i> , 2011, 285, 142-151.	2.0	39
745	PML-RAR α enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway. <i>Autophagy</i> , 2011, 7, 1132-1144.	4.3	37

#	ARTICLE	IF	CITATIONS
746	Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications. <i>Current Medicinal Chemistry</i> , 2011, 18, 3190-3210.	1.2	21
747	Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells. <i>Cell Biology International</i> , 2011, 35, 803-810.	1.4	21
748	Exploring Old Drugs for the Treatment of Hematological Malignancies. <i>Current Medicinal Chemistry</i> , 2011, 18, 1509-1514.	1.2	9
749	Oxidative Stress Induces Reactivation of Kaposi's Sarcoma-Associated Herpesvirus and Death of Primary Effusion Lymphoma Cells. <i>Journal of Virology</i> , 2011, 85, 715-724.	1.5	80
750	Modern Approaches to Treating Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 495-503.	0.8	203
751	Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 229-249.	1.1	30
752	Long-Term Remission After First-Line Single-Agent Treatment with Arsenic Trioxide of Relapsed Acute Promyelocytic Leukemia in an 8-Year-Old Boy. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 334-337.	0.3	8
753	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011056.	0.5	39
754	HISTORY OF ACUTE PROMYELOCYTIC LEUKEMIA: A TALE OF ENDLESS REVOLUTION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011067.	0.5	27
755	Tetraarsenic Hexoxide Induces Beclin-1-Induced Autophagic Cell Death as well as Caspase-Dependent Apoptosis in U937 Human Leukemic Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-11.	0.5	10
756	Current Situation and Perspectives of Clinical Study in Integrative Medicine in China. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-11.	0.5	92
757	EPIDEMIOLOGY, DIAGNOSIS AND TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN CHILDREN: THE EXPERIENCE IN CHINA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012012.	0.5	16
758	Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy. <i>Toxicology Mechanisms and Methods</i> , 2012, 22, 512-519.	1.3	14
759	Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. <i>Leukemia</i> , 2012, 26, 433-442.	3.3	149
760	Pathogenesis and treatment of leukemia: an Asian perspective. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S37-S43.	1.5	9
761	PKC δ Regulates Translation Initiation through PKR and eIF2 β in Response to Retinoic Acid in Acute Myeloid Leukemia Cells. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-17.	2.0	8
762	Targeted inhibition of VEGF-modulated survival and arsenic sensitivity in acute myeloid leukemia (AML). <i>Hematology</i> , 2012, 17, 157-162.	0.7	7
764	Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide. <i>Anti-Cancer Drugs</i> , 2012, 23, 471-482.	0.7	13

#	ARTICLE	IF	CITATIONS
765	Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations. <i>Anti-Cancer Drugs</i> , 2012, 23, 280-287.	0.7	24
766	Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38MAPK and c-Jun N-terminal kinase. <i>Anti-Cancer Drugs</i> , 2012, 23, 108-118.	0.7	18
767	Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. <i>Oncology Reports</i> , 2012, 28, 749-757.	1.2	54
768	Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines. <i>Oncology Letters</i> , 2012, 3, 1326-1330.	0.8	25
769	Molecular genetics of acute myeloid leukemia. , 0, , 204-238.		2
770	5. Molecular Target Therapy for Leukemia. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2012, 101, 102a-107a.	0.0	0
772	Molecular Targeting Therapy Against Promyelocytic Leukemia Protein Using Arsenic Acids in Experimental Intracranial Medulloblastoma. <i>Neurologia Medico-Chirurgica</i> , 2012, 52, 62-67.	1.0	2
774	Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A. <i>Oncology Reports</i> , 2012, 28, 1875-1882.	1.2	17
775	The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling. <i>Blood</i> , 2012, 120, 847-857.	0.6	33
776	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i> , 2012, 120, 1570-1580.	0.6	268
777	Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study. <i>Internal Medicine Journal</i> , 2012, 42, 948-952.	0.5	16
778	Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: Importance of the choice of species, type of cardiac tissue and perfusion time. <i>Journal of Pharmacological and Toxicological Methods</i> , 2012, 66, 135-144.	0.3	9
780	Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes. <i>Toxicology and Applied Pharmacology</i> , 2012, 262, 217-222.	1.3	23
781	Arsenic decreases RXR α -dependent transcription of CYP3A and suppresses immune regulators in hepatocytes. <i>International Immunopharmacology</i> , 2012, 12, 651-656.	1.7	15
782	Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2012, 422, 398-404.	1.0	29
783	Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function. <i>Bone</i> , 2012, 50, 1406-1415.	1.4	46
784	Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 1057-1064.	2.0	19
785	Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. <i>BMC Cancer</i> , 2012, 12, 402.	1.1	28

#	ARTICLE	IF	CITATIONS
786	Pharmacokinetics of Anticancer Materia Medica in Humans. Evidence-based Anticancer Complementary and Alternative Medicine, 2012, , 353-395.	0.1	0
787	Endoplasmic reticulum stress contributes to arsenic trioxide-induced apoptosis in drug-sensitive and -resistant leukemia cells. Leukemia Research, 2012, 36, 1526-1535.	0.4	20
788	Arsenic Trioxide (ATO) Influences the Gene Expression of Metallothioneins in Human Glioblastoma Cells. Biological Trace Element Research, 2012, 149, 331-339.	1.9	23
789	Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production. Medical Oncology, 2012, 29, 2251-2260.	1.2	7
790	The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Medical Oncology, 2012, 29, 2088-2094.	1.2	7
791	Inhibition of leukemia proliferation by a novel polysaccharide identified from Monascus-fermented dioscorea via inducing differentiation. Food and Function, 2012, 3, 758.	2.1	12
792	Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opinion on Pharmacotherapy, 2012, 13, 1031-1043.	0.9	46
793	Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy. Antioxidants and Redox Signaling, 2012, 16, 1295-1322.	2.5	591
794	A possible mechanism for combined arsenic and fluoride induced cellular and DNA damage in mice. Metallomics, 2012, 4, 78-90.	1.0	59
795	Intermittent Hypoxia and Human Diseases. , 2012, , .		16
796	Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report. Journal of Medical Case Reports, 2012, 6, 355.	0.4	8
797	Arsenic Trioxide Enhances the Radiation Sensitivity of Androgen-Dependent and -Independent Human Prostate Cancer Cells. PLoS ONE, 2012, 7, e31579.	1.1	41
798	Factors Determining Sensitivity and Resistance of Tumor Cells to Arsenic Trioxide. PLoS ONE, 2012, 7, e35584.	1.1	22
799	Base Excision Repair, the Redox Environment and Therapeutic Implications. Current Molecular Pharmacology, 2012, 5, 88-101.	0.7	21
800	Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. Journal of Hematology and Oncology, 2012, 5, 1.	6.9	85
801	Arsenic trioxide (As ₂ O ₃) inhibits murine WEHI ϵ 3 leukemia in BALB/c mice <i>in vivo</i> . Environmental Toxicology, 2012, 27, 364-371.	2.1	5
802	Calculations of structures and reaction energy profiles of As ₂ O ₃ and As ₄ O ₆ species by quantum chemical methods. International Journal of Quantum Chemistry, 2012, 112, 3320-3324.	1.0	9
803	Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond. IUBMB Life, 2012, 64, 671-675.	1.5	10

#	ARTICLE	IF	CITATIONS
804	How to manage acute promyelocytic leukemia. <i>Leukemia</i> , 2012, 26, 1743-1751.	3.3	82
805	Bleeding and thrombosis in acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 596-603.	2.0	98
806	Concomitant Induction of Heme Oxygenase-1 Attenuates the Cytotoxicity of Arsenic Species from <i>Lumbricus</i> Extract in Human Liver HepG2 Cells. <i>Chemistry and Biodiversity</i> , 2012, 9, 739-754.	1.0	11
807	Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975-2008. <i>Cancer</i> , 2012, 118, 5811-5818.	2.0	74
808	Arsenic induces apoptosis in myoblasts through a reactive oxygen species-induced endoplasmic reticulum stress and mitochondrial dysfunction pathway. <i>Archives of Toxicology</i> , 2012, 86, 923-933.	1.9	141
809	Biological responses related to agonistic, antagonistic and synergistic interactions of chemical species. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 2237-2253.	1.9	59
810	Transport routes of metalloids into and out of the cell: A review of the current knowledge. <i>Chemico-Biological Interactions</i> , 2012, 197, 47-57.	1.7	87
811	Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. <i>Tumor Biology</i> , 2012, 33, 157-172.	0.8	44
812	Arsenic trioxide versus tetraarsenic oxide in biomedical research: misunderstandings and misinterpretations. <i>BioMetals</i> , 2012, 25, 231-235.	1.8	3
813	Arsenic trioxide induces human pulmonary fibroblast cell death via the regulation of Bcl-2 family and caspase-8. <i>Molecular Biology Reports</i> , 2012, 39, 4311-4318.	1.0	14
814	Synergistic Effects of Arsenic Trioxide and Silibinin on Apoptosis and Invasion in Human Glioblastoma U87MG Cell Line. <i>Neurochemical Research</i> , 2012, 37, 370-380.	1.6	48
815	Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. <i>Environmental Toxicology</i> , 2013, 28, 267-275.	2.1	23
816	Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1903-1911.	1.9	32
817	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
818	Ultrastructural localization of F-actin using phalloidin and quantum dots in HL-60 promyelocytic leukemia cell line after cell death induction by arsenic trioxide. <i>Acta Histochemica</i> , 2013, 115, 487-495.	0.9	16
819	The quest for modernisation of traditional Chinese medicine. <i>BMC Complementary and Alternative Medicine</i> , 2013, 13, 132.	3.7	145
820	Role of Arsenic Trioxide in Acute Promyelocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2013, 14, 170-184.	1.3	40
821	A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. <i>Science China Life Sciences</i> , 2013, 56, 495-502.	2.3	48

#	ARTICLE	IF	CITATIONS
822	Combination of arsenic trioxide and chemotherapy in small cell lung cancer. <i>Lung Cancer</i> , 2013, 82, 222-230.	0.9	32
823	As ₂ O ₃ synergistically reactivate latent HIV-1 by induction of NF- κ B. <i>Antiviral Research</i> , 2013, 100, 688-697.	1.9	25
824	Inorganic arsenic impairs differentiation and functions of human dendritic cells. <i>Toxicology and Applied Pharmacology</i> , 2013, 266, 204-213.	1.3	22
825	A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1343-1352.	1.1	33
826	Targeting cancer cell mitochondria as a therapeutic approach. <i>Future Medicinal Chemistry</i> , 2013, 5, 53-67.	1.1	170
827	Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1035-1043.	1.1	11
828	Targeting peroxiredoxins against leukemia. <i>Experimental Cell Research</i> , 2013, 319, 170-176.	1.2	26
829	Sodium arsenite exposure inhibits AKT and Stat3 activation, suppresses self-renewal and induces apoptotic death of embryonic stem cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 188-200.	2.2	18
830	Unfolded protein response (UPR) signaling regulates arsenic trioxide-mediated macrophage innate immune function disruption. <i>Toxicology and Applied Pharmacology</i> , 2013, 272, 879-887.	1.3	55
831	Acute promyelocytic leukemia, centre, experience, Turkey. <i>Transfusion and Apheresis Science</i> , 2013, 48, 45-49.	0.5	5
832	$\hat{\iota}$ -Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigs. <i>European Journal of Pharmacology</i> , 2013, 705, 1-10.	1.7	12
833	Osteoblasts survive the arsenic trioxide treatment by activation of ATM-mediated pathway. <i>Biochemical Pharmacology</i> , 2013, 85, 1018-1026.	2.0	9
834	Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway. <i>Toxicology Letters</i> , 2013, 220, 61-69.	0.4	38
835	Diagnosis and Treatment of Childhood Acute Myeloid Leukemia. , 2013, , 355-373.		1
836	Redox Control of Leukemia: From Molecular Mechanisms to Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 1349-1383.	2.5	114
837	Acute Promyelocytic Leukemia. , 2013, , 403-453.		0
838	Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide. <i>Metallomics</i> , 2013, 5, 871.	1.0	24
840	Low-dose 1,25-dihydroxyvitamin D ₃ combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. <i>Oncology Reports</i> , 2013, 30, 485-491.	1.2	5

#	ARTICLE	IF	CITATIONS
841	Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As ₂ O ₃) in acute promyelocytic leukemia. <i>International Journal of Hematology</i> , 2013, 97, 717-725.	0.7	151
842	Role of HO-1 in the Arsenite-Induced Neurotoxicity in Primary Cultured Cortical Neurons. <i>Molecular Neurobiology</i> , 2013, 48, 281-287.	1.9	21
843	Repurposing as a strategy for orphan drug development, evidence from European approvals. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 473-480.	0.5	8
844	Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. <i>Leukemia and Lymphoma</i> , 2013, 54, 2041-2046.	0.6	7
845	Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. <i>Cancer Biology and Therapy</i> , 2013, 14, 897-906.	1.5	22
846	A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. <i>Neuro-Oncology</i> , 2013, 15, 783-787.	0.6	38
847	Arsenic Trioxide Stabilizes Accumulations of Adeno-Associated Virus Virions at the Perinuclear Region, Increasing Transduction <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Virology</i> , 2013, 87, 4571-4583.	1.5	35
848	Synergy against PML-RARα: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. <i>Journal of Experimental Medicine</i> , 2013, 210, 2793-2802.	4.2	121
849	MicroRNAs Contribute to Promyelocyte Apoptosis in As ₂ O ₃ -Treated APL Cells. <i>Cellular Physiology and Biochemistry</i> , 2013, 32, 1818-1829.	1.1	31
850	Urothelial Cell Intracytoplasmic Inclusions After Treatment of Promyelocytic Leukemia With Arsenic Trioxide. <i>Toxicological Sciences</i> , 2013, 134, 271-275.	1.4	8
851	Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. <i>European Journal of Haematology</i> , 2013, 91, 483-489.	1.1	19
852	Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. <i>Genes and Development</i> , 2013, 27, 1974-1985.	2.7	165
853	Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4215-4221.	0.8	149
854	Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. <i>Cancer Biology and Therapy</i> , 2013, 14, 411-416.	1.5	10
855	Acute Myeloid Leukemia, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1047-1055.	2.3	135
856	Enhancement of baicalin by hexamethylene bisacetamide on the induction of apoptosis contributes to simultaneous activation of the intrinsic and extrinsic apoptotic pathways in human leukemia cells. <i>Oncology Reports</i> , 2013, 30, 2071-2080.	1.2	19
857	Impact of chromosomal translocation and genomic instability on personalized medicine. <i>Personalized Medicine</i> , 2013, 10, 111-114.	0.8	0
858	The two opposite facets of arsenic: toxic and anticancer drug. <i>Journal of Local and Global Health Science</i> , 2013, 2013, .	0.2	7

#	ARTICLE	IF	CITATIONS
859	Aquaporin 9, a promising predictor for the cytotoxic effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts. <i>Oncology Reports</i> , 2013, 29, 2362-2368.	1.2	22
860	Expression of AFP and STAT3 Is Involved in Arsenic Trioxide-Induced Apoptosis and Inhibition of Proliferation in AFP-Producing Gastric Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e54774.	1.1	21
861	Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo. <i>PLoS ONE</i> , 2013, 8, e58491.	1.1	63
862	Resveratrol and Arsenic Trioxide Act Synergistically to Kill Tumor Cells In Vitro and In Vivo. <i>PLoS ONE</i> , 2014, 9, e98925.	1.1	31
863	ATO/ATRA/Anthracycline-Chemotherapy Sequential Consolidation Achieves Long-Term Efficacy in Primary Acute Promyelocytic Leukemia. <i>PLoS ONE</i> , 2014, 9, e104610.	1.1	13
864	Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells. <i>PLoS ONE</i> , 2014, 9, e104985.	1.1	15
865	Downregulation of hTERT: An Important As ₂ O ₃ Induced Mechanism of Apoptosis in Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2014, 9, e113199.	1.1	8
866	Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 2015, 9, 79.	2.0	26
867	Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells. <i>Oncology Reports</i> , 2014, 31, 1645-1652.	1.2	19
868	Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. <i>OncoTargets and Therapy</i> , 2014, 7, 1593.	1.0	11
869	ACUTE PROMYELOCYTIC LEUKEMIA (APL): COMPARISON BETWEEN CHILDREN AND ADULTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014032.	0.5	32
870	The Leukemias: A Half-Century of Discovery. <i>Journal of Clinical Oncology</i> , 2014, 32, 3463-3469.	0.8	52
871	Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. <i>Epigenetics</i> , 2014, 9, 774-782.	1.3	140
872	The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas. <i>European Journal of Medical Research</i> , 2014, 19, 49.	0.9	17
873	Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface. <i>Molecular Cancer</i> , 2014, 13, 251.	7.9	8
874	New frontiers of target therapy in oncology: acute promyelocytic leukemia. <i>Acta Facultatis Medicae Naissensis</i> , 2014, 31, 17-28.	0.1	0
875	Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl-dependent mechanisms. <i>Molecular Medicine Reports</i> , 2014, 10, 1519-1524.	1.1	7
876	Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma. <i>International Journal of Oncology</i> , 2014, 44, 2093-2102.	1.4	17

#	ARTICLE	IF	CITATIONS
877	Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation. <i>Journal of Neurosurgery</i> , 2014, 121, 1483-1491.	0.9	15
878	The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies. <i>Journal of Internal Medicine</i> , 2014, 276, 61-70.	2.7	17
879	Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. <i>European Journal of Haematology</i> , 2014, 93, 54-62.	1.1	11
880	Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. <i>Hematological Oncology</i> , 2014, 32, 40-46.	0.8	12
881	Sodium meta-arsenite induces reactive oxygen species-dependent apoptosis, necrosis, and autophagy in both androgen-sensitive and androgen-insensitive prostate cancer cells. <i>Anti-Cancer Drugs</i> , 2014, 25, 53-62.	0.7	14
882	Tamibarotene for the treatment of acute promyelocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 961-969.	0.5	1
883	The Novel Arsenical Darinaparsin Is Transported by Cystine Importing Systems. <i>Molecular Pharmacology</i> , 2014, 85, 576-585.	1.0	26
884	Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 39-52.	0.7	13
885	Treatment of paediatric APL: How does the therapeutic approach differ from adults?. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 69-78.	0.7	18
886	Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model. <i>Clinical and Experimental Medicine</i> , 2014, 14, 215-224.	1.9	6
887	Stripping Analysis of As(III) by Means of Screen-Printed Electrodes Modified with Gold Nanoparticles and Carbon Black Nanocomposite. <i>Electroanalysis</i> , 2014, 26, 931-939.	1.5	76
888	cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis. <i>European Journal of Pharmacology</i> , 2014, 736, 115-123.	1.7	13
889	Arsenite Binds to the RING Finger Domains of RNF20-RNF40 Histone E3 Ubiquitin Ligase and Inhibits DNA Double-Strand Break Repair. <i>Journal of the American Chemical Society</i> , 2014, 136, 12884-12887.	6.6	43
890	Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years. <i>Medical Oncology</i> , 2014, 31, 136.	1.2	2
891	Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. <i>British Journal of Cancer</i> , 2014, 111, 874-882.	2.9	57
892	Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres. <i>Acta Neuropathologica Communications</i> , 2014, 2, 31.	2.4	37
893	What is the Standard Regimen for Patients with Acute Promyelocytic Leukemia?. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 138-143.	1.2	10
894	Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. <i>International Journal of Hematology</i> , 2014, 100, 38-50.	0.7	17

#	ARTICLE	IF	CITATIONS
895	Acute promyelocytic leukemia. Best Practice and Research in Clinical Haematology, 2014, 27, 1.	0.7	2
896	Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis. Toxicology, 2014, 322, 43-50.	2.0	26
897	Polymeric micelles for GSH-triggered delivery of arsenic species to cancer cells. Biomaterials, 2014, 35, 7088-7100.	5.7	47
898	Identifying arsenic trioxide (ATO) functions in leukemia cells by using time series gene expression profiles. Gene, 2014, 535, 312-317.	1.0	2
899	Molecular Mechanisms of the Antileukemia Activities of Retinoid and Arsenic. Journal of Pharmacological Sciences, 2014, 126, 179-185.	1.1	16
900	Tetrandrine enhances the anticancer effects of arsenic trioxide in vitro. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 416-424.	0.3	15
901	Coexistence of t(15;17) and t(15;16;17) detected by fluorescence in situ hybridization in a patient with acute promyelocytic leukemia: A case report and literature review. Oncology Letters, 2014, 8, 1001-1008.	0.8	6
902	Arsenic hexoxide enhances TNF- α -induced anticancer effects by inhibiting NF- κ B activity at a safe dose in MCF-7 human breast cancer cells. Oncology Reports, 2014, 31, 2305-2311.	1.2	15
903	Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. Journal of Internal Medicine, 2015, 278, 627-642.	2.7	31
904	Bloods 70th anniversary: a rich history. Blood, 2015, 126, 2529-2530.	0.6	1
905	Fighting against hematological malignancy in China: from unique system to global impact. Science China Life Sciences, 2015, 58, 1183-1190.	2.3	11
906	Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms. Cancer Cell International, 2015, 15, 116.	1.8	25
907	Arsenic Trioxide Induces T Cell Apoptosis and Prolongs Islet Allograft Survival in Mice. Transplantation, 2015, 99, 1796-1806.	0.5	13
908	Utility and impact of early t(15;17) identification by Fluorescence <i>In Situ</i> Hybridization (<sc>FISH</sc>) in clinical decision making for patients in Acute Promyelocytic Leukemia (<sc>APL</sc>). International Journal of Laboratory Hematology, 2015, 37, 515-520.	0.7	3
909	Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European Journal of Haematology, 2015, 95, 218-229.	1.1	2
910	Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo. Drug Design, Development and Therapy, 2015, 9, 5579.	2.0	24
911	Perspective on Therapeutic Strategies of Leukemia Treatment – Focus on Arsenic Compounds. , 2015, , .		0
912	VEGFA Expression Is Inhibited by Arsenic Trioxide in HUVECs through the Upregulation of Ets-2 and miRNA-126. PLoS ONE, 2015, 10, e0135795.	1.1	20

#	ARTICLE	IF	CITATIONS
913	KML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress Pathway. <i>PLoS ONE</i> , 2015, 10, e0137589.	1.1	14
914	<i>ANXA1</i> Silencing Increases the Sensitivity of Cancer Cells to Low-concentration Arsenic Trioxide Treatment by Inhibiting ERK MAPK Activation. <i>Tumori</i> , 2015, 101, 360-367.	0.6	12
915	Cancer stem cells: a potential target for cancer therapy. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3411-3424.	2.4	53
916	QT Prolongation and Oncology Drug Development. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 341-355.	0.7	34
917	Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity. <i>International Journal of Oncology</i> , 2015, 46, 1067-78.	1.4	25
918	Delphinidin induces cytotoxicity and potentiates cytotoxic effect in combination with arsenite in an acute promyelocytic leukemia NB4 cell line. <i>Oncology Reports</i> , 2015, 34, 431-438.	1.2	21
919	Restoration of CCAAT enhancer binding protein β P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells. <i>International Journal of Oncology</i> , 2015, 47, 1685-1695.	1.4	9
920	Tetraarsenic hexoxide demonstrates anticancer activity at least in part through suppression of NF- κ B activity in SW620 human colon cancer cells. <i>Oncology Reports</i> , 2015, 33, 2940-2946.	1.2	12
921	Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 841-848.	1.4	27
922	Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma. <i>International Journal of Oncology</i> , 2015, 46, 113-122.	1.4	17
923	Neuroglobin Plays a Protective Role in Arsenite-Induced Cytotoxicity by Inhibition of Cdc42 and Rac1GTPases in Rat Cerebellar Granule Neurons. <i>Cellular Physiology and Biochemistry</i> , 2015, 36, 1613-1627.	1.1	9
924	The palladacycle, AJ-5, exhibits anti-tumour and anti-cancer stem cell activity in breast cancer cells. <i>Cancer Letters</i> , 2015, 357, 206-218.	3.2	26
925	Tetramethylpyrazine (TMP) protects against sodium arsenite-induced nephrotoxicity by suppressing ROS production, mitochondrial dysfunction, pro-inflammatory signaling pathways and programmed cell death. <i>Archives of Toxicology</i> , 2015, 89, 1057-1070.	1.9	80
926	Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure. <i>European Journal of Haematology</i> , 2015, 95, 331-335.	1.1	11
927	Role of autophagy in arsenite-induced neurotoxicity: The involvement of α -synuclein. <i>Toxicology Letters</i> , 2015, 233, 239-245.	0.4	17
928	Arsenic Trioxide and Icarin Show Synergistic Anti-leukemic Activity. <i>Cell Biochemistry and Biophysics</i> , 2015, 73, 213-219.	0.9	13
929	Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2015, 16, 11055-11086.	1.8	104
930	Arsenic trioxide inhibits accelerated allograft rejection mediated by alloreactive CD8+ memory T cells and prolongs allograft survival time. <i>Transplant Immunology</i> , 2015, 33, 30-36.	0.6	7

#	ARTICLE	IF	CITATIONS
932	Disruption of Mitotic Progression by Arsenic. <i>Biological Trace Element Research</i> , 2015, 166, 34-40.	1.9	35
933	Toward Individualized Therapy in Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2015, 1, 820.	3.4	47
934	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. <i>British Journal of Haematology</i> , 2015, 168, 646-653.	1.2	64
935	De-escalation of treatment for acute promyelocytic leukaemia?. <i>Lancet Haematology</i> , the, 2015, 2, e348-e349.	2.2	2
936	Oxidation of structural cysteine residues in thioredoxin 1 by aromatic arsenicals enhances cancer cell cytotoxicity caused by the inhibition of thioredoxin reductase 1. <i>Free Radical Biology and Medicine</i> , 2015, 89, 192-200.	1.3	27
937	Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. <i>Bone Marrow Transplantation</i> , 2015, 50, 40-44.	1.3	12
938	Exploring the modernization process of traditional medicine: a Triple Helix perspective with insights from publication and trademark statistics. <i>Social Science Information</i> , 2015, 54, 327-353.	1.1	6
939	Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1004, 98-107.	1.2	15
940	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1295-1305.	5.1	433
941	Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia. <i>Rare Cancers and Therapy</i> , 2015, 3, 119-132.	0.2	6
942	Botanical compounds and their regulation of nuclear receptor action: The case of traditional Chinese medicine. <i>Molecular and Cellular Endocrinology</i> , 2015, 401, 221-237.	1.6	28
943	Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells. <i>Cancer Letters</i> , 2015, 356, 762-772.	3.2	46
944	Progress in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 139-151.	0.2	40
945	Therapeutic and analytical applications of arsenic binding to proteins. <i>Metallomics</i> , 2015, 7, 39-55.	1.0	70
948	Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. <i>Oncotarget</i> , 2016, 7, 78226-78241.	0.8	29
949	Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. <i>Oncotarget</i> , 2016, 7, 40800-40815.	0.8	139
950	All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0158760.	1.1	33
951	The Fascinating Effects of Baicalein on Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1681.	1.8	170

#	ARTICLE	IF	CITATIONS
952	Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. <i>Journal of Biomedical Research</i> , 2017, 31, 177.	0.7	39
953	Optimal treatment strategies for high-risk acute promyelocytic leukemia. <i>Current Opinion in Hematology</i> , 2016, 23, 127-136.	1.2	19
954	Arsenic Attenuates GLI Signaling, Increasing or Decreasing its Transcriptional Program in a Context-Dependent Manner. <i>Molecular Pharmacology</i> , 2016, 89, 226-232.	1.0	8
955	Hedgehog Signaling Plays a Dual Role in Pancreatic Carcinogenesis. , 2016, , 1-22.		0
956	Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM-1 human myelodysplastic syndrome cell line. <i>Molecular Medicine Reports</i> , 2016, 14, 4180-4186.	1.1	7
957	Current first- and second-line treatment options in acute promyelocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2016, 5, 105-118.	0.7	5
958	Multidrug resistance-associated protein 4 is a determinant of arsenite resistance. <i>Oncology Reports</i> , 2016, 35, 147-154.	1.2	6
959	Clinical Implementation of Arsenic Trioxide. <i>Chinese Herbal Medicines</i> , 2016, 8, 308-313.	1.2	0
960	The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines. <i>Skin Pharmacology and Physiology</i> , 2016, 29, 63-70.	1.1	3
961	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 111.	1.8	78
962	Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer. <i>Bioinformatics</i> , 2016, 32, 1373-1379.	1.8	11
963	Hematological Practice in Hong Kong and China. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 445-456.	0.9	1
964	Serendipity in Cancer Drug Discovery: Rational or Coincidence?. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 435-450.	4.0	47
965	Paclitaxel and the dietary flavonoid fisetin: a synergistic combination that induces mitotic catastrophe and autophagic cell death in A549 non-small cell lung cancer cells. <i>Cancer Cell International</i> , 2016, 16, 10.	1.8	72
966	Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation. <i>Current Cardiology Reports</i> , 2016, 18, 52.	1.3	36
967	<i>Blood</i> 's 70th anniversary: arsenicâ€”from poison pill to magic bullet. <i>Blood</i> , 2016, 127, 1729-1730.	0.6	7
968	Osteoblasts activate the Nrf2 signalling pathway in response to arsenic trioxide treatment. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 79, 327-336.	1.2	10
969	Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide. <i>Leukemia Research</i> , 2016, 50, 116-122.	0.4	8

#	ARTICLE	IF	CITATIONS
970	<i>p</i> Azidophenylarsenoxide: An Arsenical Bait for the In Situ Capture and Identification of Cellular Arsenical Binding Proteins. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 14051-14056.	7.2	40
971	A novel all-trans retinoic acid derivative 4-amino-2-trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP. <i>Oncology Reports</i> , 2016, 36, 333-341.	1.2	30
972	Arsenic trioxide suppresses liver X receptor β and enhances cholesteryl ester transfer protein expression without affecting the liver X receptor α in HepG2 cells. <i>Chemico-Biological Interactions</i> , 2016, 258, 288-296.	1.7	5
973	Role of endoplasmic reticulum stress in drug-induced toxicity. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00211.	1.1	179
974	Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line. <i>International Journal of Oncology</i> , 2016, 49, 2319-2330.	1.4	14
975	<i>p</i> Azidophenylarsenoxide: An Arsenical Bait for the In Situ Capture and Identification of Cellular Arsenical Binding Proteins. <i>Angewandte Chemie</i> , 2016, 128, 14257-14262.	1.6	3
976	Redox-Active Metal Complexes in Trypanosomatids. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2016, , 669-681.	0.4	0
977	Hijacking microglial glutathione by inorganic arsenic impels bystander death of immature neurons through extracellular cystine/glutamate imbalance. <i>Scientific Reports</i> , 2016, 6, 30601.	1.6	26
978	Herb-target interaction network analysis helps to disclose molecular mechanism of traditional Chinese medicine. <i>Scientific Reports</i> , 2016, 6, 36767.	1.6	26
979	Comparative cytotoxicity of fourteen trivalent and pentavalent arsenic species determined using real-time cell sensing. <i>Journal of Environmental Sciences</i> , 2016, 49, 113-124.	3.2	131
980	Endothelial to mesenchymal transition contributes to arsenic-trioxide-induced cardiac fibrosis. <i>Scientific Reports</i> , 2016, 6, 33787.	1.6	44
981	The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. <i>Cancer</i> , 2016, 122, 1160-1168.	2.0	22
982	Current standard treatment of adult acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 841-854.	1.2	60
983	Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. <i>Cancer Cell International</i> , 2016, 16, 37.	1.8	16
984	Differential transcriptional regulation of hypoxia-inducible factor-1 α by arsenite under normoxia and hypoxia: involvement of Nrf2. <i>Journal of Molecular Medicine</i> , 2016, 94, 1153-1166.	1.7	27
985	Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth. <i>International Journal of Oncology</i> , 2016, 48, 235-242.	1.4	19
986	A novel dielectrophoresis activated cell sorter (DACS) to evaluate the apoptotic rate of K562 cells treated with arsenic trioxide (As ₂ O ₃). <i>Sensors and Actuators A: Physical</i> , 2016, 242, 1-8.	2.0	10
987	Synergy in traditional Chinese medicine. <i>Lancet Oncology</i> , The, 2016, 17, e39.	5.1	19

#	ARTICLE	IF	CITATIONS
988	Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report. <i>Leukemia Research Reports</i> , 2016, 5, 11-13.	0.2	3
989	Inorganic phosphate-triggered release of anti-cancer arsenic trioxide from a self-delivery system: an in vitro and in vivo study. <i>Nanoscale</i> , 2016, 8, 6094-6100.	2.8	15
990	Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21WAF1/CIP1 expression via epigenetic remodeling in LNCaP and PC3 cell lines. <i>Life Sciences</i> , 2016, 148, 41-52.	2.0	32
991	Swallowing a bitter pill—oral arsenic trioxide for acute promyelocytic leukemia. <i>Blood Reviews</i> , 2016, 30, 201-211.	2.8	22
992	Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1009-1010, 55-65.	1.2	29
993	2,3,5,6-Tetramethylpyrazine (TMP) down-regulated arsenic-induced heme oxygenase-1 and ARS2 expression by inhibiting Nrf2, NF- κ B, AP-1 and MAPK pathways in human proximal tubular cells. <i>Archives of Toxicology</i> , 2016, 90, 2187-2200.	1.9	41
994	IL-18-induced interaction between IMP3 and HuR contributes to COX-2 mRNA stabilization in acute myeloid leukemia. <i>Journal of Leukocyte Biology</i> , 2016, 99, 131-141.	1.5	21
995	Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 646-651.	0.5	5
996	Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide: Experience from a Tertiary Care Center in India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 45-48.	0.3	3
997	Dithiothreitol enhanced arsenic trioxide-induced cell apoptosis in cultured oral cancer cells via mitochondrial dysfunction and endoplasmic reticulum stress. <i>Environmental Toxicology</i> , 2017, 32, 17-27.	2.1	14
998	Scientific collaboration in indigenous knowledge in context: Insights from publication and co-publication network analysis. <i>Technological Forecasting and Social Change</i> , 2017, 117, 57-69.	6.2	13
999	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 20-34.	2.0	105
1000	Chemotherapy for Leukemia. , 2017, , .		2
1001	Arsenic Trioxide: Clinical Pharmacology and Therapeutic Results. , 2017, , 221-238.		4
1002	Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2017, 331, 54-61.	1.3	13
1003	Downregulation of androgen receptors by NaAsO ₂ via inhibition of AKT κ B and HSP90 in castration resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1128-1136.	1.2	7
1004	Arsenic trioxide increases expression of secreted frizzled-related protein 1 gene and inhibits the WNT/ β -catenin signaling pathway in Jurkat cells. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2050-2055.	0.8	6
1005	Mechanism of arsenite toxicity in embryonic stem cells. <i>Journal of Applied Toxicology</i> , 2017, 37, 1151-1161.	1.4	1

#	ARTICLE	IF	CITATIONS
1006	On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia. <i>Leukemia Research Reports</i> , 2017, 7, 29-32.	0.2	15
1007	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283.	0.6	214
1008	Distinct TP73- and DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1357-1370.	1.5	14
1009	Arsenic trioxide exposure impairs testicular morphology in adult male mice and consequent fetus viability. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2017, 80, 1166-1179.	1.1	36
1010	Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation. <i>Oncology Letters</i> , 2017, 14, 3103-3109.	0.8	19
1011	Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. <i>Oncology Letters</i> , 2017, 14, 3243-3248.	0.8	9
1012	Acute Promyelocytic Leukemia: A Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 543-544.	0.2	14
1013	Induction of telomere shortening and cellular apoptosis by sodium meta-arsenite in human cancer cell lines. <i>Animal Cells and Systems</i> , 2017, 21, 241-254.	0.8	7
1014	PTEN is a negative regulator of mitotic checkpoint complex during the cell cycle. <i>Experimental Hematology and Oncology</i> , 2017, 6, 19.	2.0	15
1015	Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells. <i>Virology Journal</i> , 2017, 14, 121.	1.4	8
1016	Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 129-138.	1.8	48
1017	Arsenic trioxide intravenous infusion combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with pulmonary metastasis: Long-term outcome analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 295-300.	1.4	27
1018	Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2305-2313.	1.0	13
1019	Influences of Realgar-Indigo naturalis, A Traditional Chinese Medicine Formula, on the Main CYP450 Activities in Rats Using a Cocktail Method. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-9.	0.5	4
1020	Calcium homeostasis and endoplasmic reticulum stress are involved in Salvianolic acid B-offered protection against cardiac toxicity of arsenic trioxide. <i>Oncotarget</i> , 2017, 8, 97384-97393.	0.8	16
1021	Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1585-1601.	1.0	66
1022	Ataxia telangiectasia and rad3 related (ATR)-promyelocytic leukemia protein (PML) pathway of the DNA damage response in the brain of rats administered arsenic trioxide. <i>Journal of Toxicologic Pathology</i> , 2017, 30, 333-337.	0.3	3
1023	The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide. <i>Oncotarget</i> , 2017, 8, 90905-90915.	0.8	12

#	ARTICLE	IF	CITATIONS
1024	Dual Roles of Oxidative Stress in Metal Carcinogenesis. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2017, 36, 345-376.	0.6	50
1025	Catalase down-regulation in cancer cells exposed to arsenic trioxide is involved in their increased sensitivity to a pro-oxidant treatment. <i>Cancer Cell International</i> , 2018, 18, 24.	1.8	38
1027	Switching from all-transretinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 3013-3015.	0.6	1
1028	Arsenic trioxide: insights into its evolution to an anticancer agent. <i>Journal of Biological Inorganic Chemistry</i> , 2018, 23, 313-329.	1.1	100
1030	Eugenol, a plant-derived phenolic nutraceutical, protects thiol (SH) group in myocardium from ROS-mediated oxidation under chemotherapeutic stress induced by arsenic trioxide in vivo model study. <i>Drug and Chemical Toxicology</i> , 2018, 41, 352-357.	1.2	16
1031	Modulation of thiol-dependent redox system by metal ions via thioredoxin and glutaredoxin systems. <i>Metallomics</i> , 2018, 10, 218-228.	1.0	83
1032	Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2018, 100, 344-350.	1.1	10
1033	Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2018, 97, 409-416.	0.8	10
1034	Cure of APL Without Chemotherapy. , 2018, , 133-151.		0
1035	Prognostic Factors in APL. , 2018, , 87-98.		0
1036	First-Line Therapy: ATRA-ATO/Reduced Chemotherapy Approach. , 2018, , 113-132.		0
1037	Management of Treatment-Related Complications in APL. , 2018, , 257-267.		0
1038	Hedgehog Signaling Plays a Dual Role in Pancreatic Carcinogenesis. , 2018, , 409-430.		1
1039	APL in Developing Countries: ATO-Based Approach. , 2018, , 217-229.		0
1041	Health risk assessment of arsenic in Realgar and NiuHuangJieDu Tablets based on pharmacokinetic study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 48, 81-86.	1.5	15
1042	Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment. <i>Talanta</i> , 2018, 184, 446-451.	2.9	24
1043	Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. <i>European Journal of Haematology</i> , 2018, 100, 154-162.	1.1	6
1044	Effects of vinegar egg on growth inhibition, differentiation human leukemic U937 cells and its immunomodulatory activity. <i>Journal of Food and Drug Analysis</i> , 2018, 26, 731-740.	0.9	8

#	ARTICLE	IF	CITATIONS
1045	The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. <i>Cancer Cell</i> , 2018, 34, 823-839.e7.	7.7	93
1046	Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2018, 41, E11-E16.	0.9	13
1047	Toward the potential cure of leukemias in the next decade. <i>Cancer</i> , 2018, 124, 4301-4313.	2.0	36
1048	Acute Promyelocytic Leukemia. <i>Journal of Nepal Paediatric Society</i> , 2018, 37, 270-272.	0.1	1
1049	Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status. <i>Life Sciences</i> , 2018, 212, 182-193.	2.0	4
1050	Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death. <i>Cancer Management and Research</i> , 2018, Volume 10, 3619-3627.	0.9	5
1051	Realgar, a traditional Chinese medicine, induces apoptosis of HPV16-positive cervical cells through a HPV16 E7-related pathway. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3459-3469.	2.0	16
1052	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
1053	Proteomics in Acute Myeloid Leukemia. , 2018, , .		1
1054	Acute Promyelocytic Leukemia. , 2018, , .		2
1055	Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 229-236.	1.1	15
1056	Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 1-16.	1.9	45
1057	What has traditional Chinese medicine delivered for modern medicine?. <i>Expert Reviews in Molecular Medicine</i> , 2018, 20, e4.	1.6	198
1058	Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo. <i>Cancer Cell International</i> , 2018, 18, 113.	1.8	31
1059	Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy. <i>Hematological Oncology</i> , 2018, 36, 584-590.	0.8	9
1060	2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia. <i>Haematologica</i> , 2019, 104, 102-112.	1.7	10
1061	Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. <i>Leukemia</i> , 2019, 33, 358-370.	3.3	27
1062	Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells. <i>Acta Oncologica</i> , 2019, 58, 1594-1602.	0.8	11

#	ARTICLE	IF	CITATIONS
1063	Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells. <i>Scientific Reports</i> , 2019, 9, 9414.	1.6	30
1064	Novel synthetic tosyl chloride-berbamine regresses lethal MYC-positive leukemia by targeting CaMKII β /Myc axis. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109134.	2.5	7
1065	Role of differential proteomics in studying pharmacological mechanisms of traditional Chinese medicines. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 424-439.	0.9	0
1066	Current and emerging treatments for acute promyelocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 453-461.	0.5	1
1067	Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RAR α partially through the ubiquitin-proteasome pathway. <i>Archives of Pharmacal Research</i> , 2019, 42, 684-694.	2.7	7
1068	QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics. <i>Current Treatment Options in Oncology</i> , 2019, 20, 55.	1.3	24
1069	The simpler, the better: oral arsenic for acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 597-605.	0.6	95
1070	Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound after Termination of ART in Chronically SIV α -infected Macaques. <i>Advanced Science</i> , 2019, 6, 1900319.	5.6	21
1071	The role of thioredoxin system in cancer: strategy for cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 453-470.	1.1	101
1072	Arsenic, As. , 2019, , 463-481.		4
1073	Vanadium Dioxide Nanocoating Induces Tumor Cell Death through Mitochondrial Electron Transport Chain Interruption. <i>Global Challenges</i> , 2019, 3, 1800058.	1.8	33
1074	Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity. <i>Toxicological Sciences</i> , 2019, 169, 108-121.	1.4	24
1075	Identification of a point mutation PMLS214L-RAR α that alters PML body organization, dynamics and SUMOylation. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 518-523.	1.0	1
1076	Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia. <i>Oncology and Therapy</i> , 2019, 7, 33-65.	1.0	48
1077	Sodium arsenite augments sensitivity of <i>Echinococcus granulosus</i> protoscoleces to albendazole. <i>Experimental Parasitology</i> , 2019, 200, 55-60.	0.5	3
1078	Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 119-130.	1.0	3
1079	The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress. <i>Molecules</i> , 2019, 24, 543.	1.7	20
1080	When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. <i>Chemotherapy</i> , 2019, 64, 238-247.	0.8	19

#	ARTICLE	IF	CITATIONS
1081	Evaluation of Traditional Chinese Medicine Herbs in Oncology Clinical Trials. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 367-371.	1.0	16
1082	Pressure-Induced Phase Transitions in Sesquioxides. <i>Crystals</i> , 2019, 9, 630.	1.0	21
1083	Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27542.	0.8	14
1084	Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 711-719.	0.6	4
1085	In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment. <i>Leukemia Research</i> , 2019, 76, 11-14.	0.4	11
1086	Arsenic trioxide ameliorates murine colon inflammation through inflammatory cell enzymatic modulation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 259-270.	1.4	5
1087	Past and Current Arsenic Poisonings. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , 1-11.	0.1	4
1088	Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer. <i>Drug Safety</i> , 2019, 42, 263-279.	1.4	77
1089	An Overview on Arsenic Trioxide-Induced Cardiotoxicity. <i>Cardiovascular Toxicology</i> , 2019, 19, 105-119.	1.1	53
1090	Pharmacokinetic Properties of Arsenic Species after Intravenous and Intra-gastric Administration of Arsenic Trioxide Solution in Cynomolgus Macaques Using HPLC-ICP-MS. <i>Molecules</i> , 2019, 24, 241.	1.7	11
1091	Curative strategies in APL. <i>Seminars in Hematology</i> , 2019, 56, 131-138.	1.8	6
1092	Arsenic trioxide inhibits the differentiation of fibroblasts to myofibroblasts through nuclear factor erythroid 2-related factor 2 (NFE2L2) protein and the Smad2/3 pathway. <i>Journal of Cellular Physiology</i> , 2019, 234, 2606-2617.	2.0	15
1093	The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China. <i>Cancer</i> , 2020, 126, 311-321.	2.0	10
1094	Arsenite suppresses the transcriptional activity of EVI1 through the binding to CCHC-type Zn finger domain. <i>Biochemical and Biophysical Research Communications</i> , 2020, 529, 910-915.	1.0	1
1095	Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs. <i>Metallomics</i> , 2020, 12, 1627-1636.	1.0	23
1096	SUMO: From Bench to Bedside. <i>Physiological Reviews</i> , 2020, 100, 1599-1619.	13.1	155
1097	UK Experience of an Alternative ATO Dosing Regimen in APL. <i>Frontiers in Oncology</i> , 2020, 10, 594129.	1.3	2
1098	Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukemia: A Historical Account From Bedside to Bench to Bedside. <i>Frontiers in Oncology</i> , 2020, 10, 1294.	1.3	14

#	ARTICLE	IF	CITATIONS
1099	Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. <i>Toxicology and Applied Pharmacology</i> , 2020, 409, 115299.	1.3	29
1100	Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia. <i>Cells</i> , 2020, 9, 1921.	1.8	11
1101	Combinatorial Low Dose Arsenic Trioxide and Cisplatin Exacerbates Autophagy via AMPK/STAT3 Signaling on Targeting Head and Neck Cancer Initiating Cells. <i>Frontiers in Oncology</i> , 2020, 10, 463.	1.3	17
1102	Changing faces of stress: Impact of heat and arsenite treatment on the composition of stress granules. <i>Wiley Interdisciplinary Reviews RNA</i> , 2020, 11, e1596.	3.2	12
1103	NLS-RAR β blocks cell differentiation by inhibiting the retinoic acid signalling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2020, 528, 276-284.	1.0	1
1104	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. <i>Haematologica</i> , 2020, 105, 1567-1574.	1.7	25
1105	ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity. <i>Advanced Science</i> , 2020, 7, 1902130.	5.6	9
1106	Virulence-Inhibiting Herbal Compound Falcarindiol Significantly Reduced Mortality in Mice Infected with <i>Pseudomonas aeruginosa</i> . <i>Antibiotics</i> , 2020, 9, 136.	1.5	10
1107	Synthesis and Characterization of Arsenic(III) Oxide Nanoparticles as Potent Inhibitors of MCF 7 Cell Proliferation through Proapoptotic Mechanism. <i>BioNanoScience</i> , 2020, 10, 420-429.	1.5	8
1108	Analysis on Situation of Traditional Chinese Medicine Development and Protection Strategies in China. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 943-946.	0.7	6
1109	Old dog, new trick: Trivalent arsenic as an immunomodulatory drug. <i>British Journal of Pharmacology</i> , 2020, 177, 2199-2214.	2.7	16
1110	Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon-inhibition. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1061-1072.	5.7	12
1111	Modern traditional Chinese medicine: Identifying, defining and usage of TCM components. <i>Advances in Pharmacology</i> , 2020, 87, 113-158.	1.2	33
1112	Identification of Histone H3 and H4 Amino Acid Residues Important for the Regulation of Arsenite Stress Signaling in <i>Saccharomyces cerevisiae</i> . <i>Chemical Research in Toxicology</i> , 2020, 33, 817-833.	1.7	4
1113	JSH practical guidelines for hematological malignancies, 2018: I. Leukemia—2. Acute promyelocytic leukemia (APL). <i>International Journal of Hematology</i> , 2020, 111, 747-760.	0.7	2
1114	Systematic age-, organ-, and diet-associated ionome remodeling and the development of ionomic aging clocks. <i>Ageing Cell</i> , 2020, 19, e13119.	3.0	15
1115	Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2649.	1.8	16
1116	Arsenite Exposure Displaces Zinc from ZRANB2 Leading to Altered Splicing. <i>Chemical Research in Toxicology</i> , 2020, 33, 1403-1417.	1.7	19

#	ARTICLE	IF	CITATIONS
1117	Progresses and emerging trends of arsenic research in the past 120 years. <i>Critical Reviews in Environmental Science and Technology</i> , 2021, 51, 1306-1353.	6.6	37
1118	ECG Markers of Cardiovascular Toxicity in Adult and Pediatric Cancer Treatment. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	10
1119	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	31
1120	Drug Repurposing: An Avenue Toward Stress Medicine in Cancer Therapy. , 2021, , 237-262.		0
1121	Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1267-1270.	0.6	4
1123	Antiangiogenic effect of arsenic trioxide in HUVECs by FoxO3a-regulated autophagy. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22728.	1.4	1
1124	Arsenic hexoxide has differential effects on cell proliferation and genome-wide gene expression in human primary mammary epithelial and MCF7 cells. <i>Scientific Reports</i> , 2021, 11, 3761.	1.6	10
1125	Evolving Chemotherapy Free Regimens for Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 621566.	1.3	7
1126	Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 597601.	1.3	9
1127	OGP46 Induces Differentiation of Acute Myeloid Leukemia Cells via Different Optimal Signaling Pathways. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 652972.	1.8	5
1128	Cytotoxic Effects of Arsenite in Combination With Gamabufotalin Against Human Glioblastoma Cell Lines. <i>Frontiers in Oncology</i> , 2021, 11, 628914.	1.3	4
1129	Baicalin Represses Type Three Secretion System of <i>Pseudomonas aeruginosa</i> through PQS System. <i>Molecules</i> , 2021, 26, 1497.	1.7	13
1130	Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 53-63.	0.4	2
1131	Engineering 2D Arsenic-Phosphorus Theranostic Nanosheets. <i>Advanced Functional Materials</i> , 2021, 31, 2101660.	7.8	11
1132	Tetraarsenic oxide affects non-coding RNA transcriptome through deregulating polycomb complexes in MCF7 cells. <i>Advances in Biological Regulation</i> , 2021, 80, 100809.	1.4	4
1133	Hypothesis of using albumin to improve drug efficacy in cancers accompanied by hypoalbuminemia. <i>Xenobiotica</i> , 2021, 51, 778-785.	0.5	1
1134	Neuroglobin alleviates arsenic-induced neuronal damage. <i>Environmental Toxicology and Pharmacology</i> , 2021, 84, 103604.	2.0	6
1136	Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1173-1182.	1.3	2

#	ARTICLE	IF	CITATIONS
1137	Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein. <i>British Journal of Haematology</i> , 2021, 194, 1085-1090.	1.2	2
1138	Acute promyelocytic leukemia current treatment algorithms. <i>Blood Cancer Journal</i> , 2021, 11, 123.	2.8	80
1139	Successful treatment of acute promyelocytic leukemia in a patient undergoing hemodialysis with arsenic trioxide. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04300.	0.2	1
1140	Successful treatment of acute promyelocytic leukemia in a patient under hemodialysis with arsenic trioxide. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04417.	0.2	0
1141	Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. <i>Medicinal Research Reviews</i> , 2022, 42, 374-398.	5.0	26
1142	The toxicity and safety of Chinese medicine from the bench to the bedside. <i>Journal of Herbal Medicine</i> , 2021, 28, 100450.	1.0	6
1143	Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113451.	2.6	31
1144	The translational values of TRIM family in pan-cancers: From functions and mechanisms to clinics. , 2021, 227, 107881.		27
1145	Arsenic: A Global Environmental Challenge. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 47-63.	4.2	127
1147	Drug Resistance in Cancer Cells. , 2009, , .		3
1148	Resistance to Differentiation Therapy. , 2009, , 233-255.		2
1149	Current approaches to acute promyelocytic leukemia. , 1999, 99, 125-153.		4
1150	Pharmacokinetics, Metabolism, and Carcinogenicity of Arsenic. <i>Reviews of Environmental Contamination and Toxicology</i> , 2001, 169, 165-214.	0.7	61
1151	The Design of Selective and Non-selective Combination Therapy for Acute Promyelocytic Leukemia. , 2007, 313, 245-269.		10
1152	Arsenic Trioxide and Acute Promyelocytic Leukemia: Clinical and Biological. <i>Current Topics in Microbiology and Immunology</i> , 2007, 313, 129-144.	0.7	25
1153	Relapsed and Refractory Acute Myeloid Leukemia. , 2008, , 57-76.		2
1154	<i>Saccharomyces cerevisiae</i> as a Model Organism for Elucidating Arsenic Tolerance Mechanisms. , 2011, , 87-112.		13
1155	Arsenic. Can This Toxic Metalloid Sustain Life?. <i>Metal Ions in Life Sciences</i> , 2013, 13, 475-498.	2.8	9

#	ARTICLE	IF	CITATIONS
1156	Biotransformation of arsenic and toxicological implication of arsenic metabolites. Archives of Toxicology, 2020, 94, 2587-2601.	1.9	39
1157	Acute Myeloid Leukemia in Adults. , 2008, , 2215-2234.		3
1158	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. , 2009, , 331-402.		3
1159	Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 308-347.	0.8	14
1160	Therapeutic approaches to the modulation of apoptosis. Essays in Biochemistry, 2003, 39, 131-153.	2.1	13
1161	Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies. Leukemia and Lymphoma, 2001, 42, 1265-1273.	0.6	14
1162	Arsenic inhibition of telomerase transcription leads to genetic instability. Journal of Clinical Investigation, 2001, 108, 1541-1547.	3.9	101
1163	Ham-Wasserman Lecture. Hematology American Society of Hematology Education Program, 2003, 2003, 1-13.	0.9	1
1164	Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells. Blood, 1998, 91, 4300-4310.	0.6	18
1165	Trivalent Antimonials Induce Degradation of the PML-RAR α Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells. Blood, 1998, 92, 4308-4316.	0.6	6
1166	Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RAR α Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood, 1998, 92, 784-789.	0.6	2
1167	Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RAR α Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy. Blood, 1998, 92, 1172-1183.	0.6	6
1168	Arsenic Trioxide and Melarsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RAR α Independent Manner. Blood, 1998, 92, 1497-1504.	0.6	12
1169	Malignant Cells Can Be Sensitized to Undergo Growth Inhibition and Apoptosis by Arsenic Trioxide Through Modulation of the Glutathione Redox System. Blood, 1999, 93, 268-277.	0.6	31
1170	Arsenic Trioxide Selectively Induces Acute Promyelocytic Leukemia Cell Apoptosis Via a Hydrogen Peroxide-Dependent Pathway. Blood, 1999, 94, 2102-2111.	0.6	35
1172	Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 2000, 96, 1525-1530.	0.6	6
1173	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood, 2002, 99, 1014-1022.	0.6	4
1174	Arsenic Trioxide Prevents Osteosarcoma Growth by Inhibition of Gli Transcription via DNA Damage Accumulation. PLoS ONE, 2013, 8, e69466.	1.1	60

#	ARTICLE	IF	CITATIONS
1175	SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery. PLoS ONE, 2013, 8, e79568.	1.1	96
1176	Arsenic Trioxide Induces Apoptosis in Human Platelets via C-Jun NH2-Terminal Kinase Activation. PLoS ONE, 2014, 9, e86445.	1.1	19
1177	Increased Growth-Inhibitory and Cytotoxic Activity of Arsenic Trioxide in Head and Neck Carcinoma Cells with Functional p53 Deficiency and Resistance to EGFR Blockade. PLoS ONE, 2014, 9, e98867.	1.1	9
1178	Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance. PLoS ONE, 2015, 10, e0121912.	1.1	43
1179	Arsenic Trioxide Sensitizes Glioblastoma to a Myc Inhibitor. PLoS ONE, 2015, 10, e0128288.	1.1	12
1180	Low-Concentration Arsenic Trioxide Inhibits Skeletal Myoblast Cell Proliferation via a Reactive Oxygen Species-Independent Pathway. PLoS ONE, 2015, 10, e0137907.	1.1	9
1181	Acute Myeloid Leukemia Acquiring Promyelocytic Leukemia-Retinoic Acid Receptor Alpha at Relapse. World Journal of Oncology, 2019, 10, 153-156.	0.6	1
1182	Induction treatments for acute promyelocytic leukemia: a network meta-analysis. Oncotarget, 2016, 7, 71974-71986.	0.8	4
1183	Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget, 2016, 7, 83359-83377.	0.8	8
1184	Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy. Oncotarget, 2017, 8, 114210-114225.	0.8	25
1185	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. Oncotarget, 2020, 11, 46-61.	0.8	1
1186	Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction. Oncotarget, 2016, 7, 12682-12692.	0.8	31
1187	Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects. Current Drug Metabolism, 2013, 14, 1029-1041.	0.7	22
1188	Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma. Mini-Reviews in Medicinal Chemistry, 2016, 16, 430-454.	1.1	42
1189	Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide. Current Cancer Drug Targets, 2020, 20, 115-129.	0.8	8
1190	Combination Therapy with Arsenic Trioxide for Hematological Malignancies. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 504-510.	0.9	33
1191	Reactive Oxygen Species, Cancer and Anti-Cancer Therapies. Current Chemical Biology, 2009, 3, 22-46.	0.2	53
1192	The Treatment of Elderly Patients With Acute Myeloid Leukemia. Deutsches Ärzteblatt International, 2011, 108, 863-70.	0.6	43

#	ARTICLE	IF	CITATIONS
1193	Effect of arsenic trioxide on human hepatocarcinoma in nude mice. World Journal of Gastroenterology, 2004, 10, 3677.	1.4	22
1194	Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World Journal of Gastroenterology, 2006, 12, 5780.	1.4	31
1195	Effect of arsenic trioxide on human hepatoma cell line BEL-7402 cultured <i>in vitro</i> . World Journal of Gastroenterology, 2000, 6, 681.	1.4	19
1196	Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World Journal of Gastroenterology, 2001, 7, 702.	1.4	41
1197	Effect of arsenic trioxide on rat hepatocarcinoma and its renal cytotoxicity. World Journal of Gastroenterology, 2003, 9, 930.	1.4	22
1198	P53-induced gene 11 (PIG11) involved in arsenic trioxide-induced apoptosis in human gastric cancer MGC-803 cells. Oncology Reports, 0, , .	1.2	7
1199	Newly Synthesized Palladium (II) Complex ASH10 Induces Apoptosis and Autophagy in Breast Cancer Cells. International Journal of Cancer Research, 2020, 16, 40-47.	0.2	1
1200	Pharmacokinetic of Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia Patients. Journal of Applied Sciences, 2008, 8, 4617-4623.	0.1	6
1201	Tetraarsenic Oxide-mediated Apoptosis in a Cervical Cancer Cell Line, SiHa. Cancer Research and Treatment, 2009, 37, 307.	1.3	4
1202	DELILE EXHIBITS A POTENTIAL FOR THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA. Global Journal of Advanced Engineering Technologies and Sciences, 2018, 5, 1-9.	0.0	3
1203	Role of autophagy in acute myeloid leukemia therapy. Chinese Journal of Cancer, 2013, 32, 130-135.	4.9	26
1204	Acute Promyelocytic Leukemia: A Model Disease for Targeted Cancer Therapy. , 0, , .		1
1205	The cure of leukemia through the optimist's prism. Cancer, 2022, 128, 240-259.	2.0	17
1206	A Novel Acute Promyelocytic Leukemia Model: From Cell to Murine System. , 2000, , 133-142.		0
1207	All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia. Hamatologie Und Bluttransfusion, 2001, , 565-569.	0.0	1
1208	El sÃndrome del ATRA como complicaciÃ³n del tratamiento en la leucemia promielocÃtica aguda. Anales De Medicina Interna, 2001, 18, .	0.1	0
1209	Mechanism of Action and Metabolism of Antineoplastic and Chemopreventive Agents. , 2002, , 201-360.		0
1210	Effect of Arsenic Trioxide in TRAIL (Tumor Necrosis Factor-related Apoptosis Inducing) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 6 472-477.	1.3	0

#	ARTICLE	IF	CITATIONS
1211	APL: A Classic Tale of Bench to Bedside. , 2007, , 193-228.		1
1212	AML in Older Adults. , 2007, , 373-384.		1
1213	Pharmacogenomics of Biotic and Abiotic Natural Products Derived from Traditional Chinese Medicine for Cancer Therapy. , 2009, , .		0
1214	Inhibition of cell growth and apoptosis in CaSki, cervical cancer cell line by arsenic compounds. Korean Journal of Obstetrics and Gynecology, 2010, 53, 616.	0.1	0
1215	Leukemia Stem Cells. , 2012, , 85-103.		0
1217	Anticancer Effects of Intermittent Hypoxia in Acute Myeloid Leukemia. , 2012, , 229-238.		0
1218	Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia and Glioma. , 2012, , 431-451.		0
1219	Differentiation Therapy in Thyroid Carcinoma. , 0, , .		0
1222	Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines. Blood, 1997, 90, 562-570.	0.6	4
1223	Anti-cancer Potentials of Rhus verniciflua Stokes, Ulmus davidiana var. japonica Nakai and Arsenium Sublimatum in Human Gastric Cancer AGS Cells. Journal of Life Science, 2015, 25, 849-860.	0.2	4
1226	A short review of arsenic-induced toxicity. Journal of Preventive Veterinary Medicine, 2016, 40, 46-52.	0.1	2
1227	PHA-Induced Peripheral Blood Cytogenetics and Molecular Anlysis : a Valid Diagnostic and Follow-up Modality For Acute Primyelocytic Leukemia Patients Treated With ATRA and/or Arsenic Tri-oxide. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1999-2006.	0.5	1
1228	The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL). , 2017, , 213-220.		0
1229	Review of Arsenic Induced Alternation In Animals By Its Toxicity. SSRN Electronic Journal, 0, , .	0.4	1
1230	Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia. Journal of Hematology (Brossard, Quebec), 2020, 9, 89-92.	0.4	4
1231	Experimental and Clinical Research Progress of Arsenic Trioxide in Treating Hepatocellular Carcinoma. Traditional Chinese Medicine, 2020, 09, 34-39.	0.1	0
1232	Traditional medicine exemplified by traditional Chinese medicine. , 2020, , 108-117.		0
1233	Development of Realgar Nanotherapeutics for Cancer Treatments. , 2020, , 421-454.		1

#	ARTICLE	IF	CITATIONS
1235	Arsenic Trioxide and Leukemia. , 2005, , 251-272.		0
1238	Cancer metabolism and tumor microenvironment: fostering each other?. Science China Life Sciences, 2022, 65, 236-279.	2.3	68
1239	Prospects for the production of radioisotopes and radiobioconjugates for theranostics. Bio-Algorithms and Med-Systems, 2022, 17, 241-257.	1.0	13
1240	Cellular and molecular mechanism of arsenic trioxide in the treatment of hematopoietic malignancies. , 1999, 5, 82-88.		0
1241	Modulation of gene expression networks underlying Realgar-Induced differentiation of acute promyelocytic leukemia cells. , 2002, 8, 195-199.		0
1242	Effect of arsenic trioxide on cervical cancer and its mechanisms. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	7
1244	Arsenic Nanoparticles are Effective in Reducing 3-Methylcholanthrene Induced Carcinogenesis in Murine Fibrosarcoma by Promoting Anti-tumorigenic Inflammation. BioNanoScience, 0, , .	1.5	1
1245	Arsenic compounds induce apoptosis by activating the MAPK and caspase pathways in FaDu oral squamous carcinoma cells. International Journal of Oncology, 2022, 60, .	1.4	6
1246	Urolithin A attenuates arsenic-induced gut barrier dysfunction. Archives of Toxicology, 2022, 96, 987-1007.	1.9	10
1247	Pyroptosis and pyroptosis-inducing cancer drugs. Acta Pharmacologica Sinica, 2022, 43, 2462-2473.	2.8	41
1248	Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Toxicology and Applied Pharmacology, 2022, 441, 115972.	1.3	6
1249	Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes. Journal of Cellular and Molecular Medicine, 2022, , .	1.6	7
1250	F-box protein FBXO41 plays vital role in arsenic trioxide-mediated autophagic death of cancer cells. Toxicology and Applied Pharmacology, 2022, 441, 115973.	1.3	1
1251	Herbo-metallic ethnomedicine "Malla Sindoor"™ ameliorates lung inflammation in murine model of allergic asthma by modulating cytokines status and oxidative stress. Journal of Ethnopharmacology, 2022, 292, 115120.	2.0	2
1252	A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms. Cancer Research Communications, 2022, 2, 258-276.	0.7	0
1253	CHAPTER 5. Medicinal Arsenic. , 0, , 129-160.		0
1254	Arsenicals: Past, Present, and Future. , 0, , 189-204.		0
1261	Arsenic in Drinking Water and Incidences of Leukemia and Lymphoma: Implication for Its Dual Effects in Carcinogenicity. Frontiers in Public Health, 2022, 10, 863882.	1.3	5

#	ARTICLE	IF	CITATIONS
1262	Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization. <i>Drug Delivery</i> , 2022, 29, 1447-1456.	2.5	1
1263	Column optimization of adsorption and evaluation of bed parameters-based on removal of arsenite ion using rice husk. <i>Environmental Science and Pollution Research</i> , 2022, 29, 72279-72293.	2.7	2
1264	The whole transcriptome analysis and the circRNA-lncRNA network construction in arsenic trioxide-treated mice myocardium. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113183.	2.5	9
1265	A Scientometric and Visualization Analysis of Arsenic for Acute Promyelocytic Leukemia Studies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1267	Evolving of Treatment Paradigms and Challenges in Acute Promyelocytic Leukaemia: A Real-World Analysis of 1105 Patients Over the Last Three Decades. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1268	A scientometric and visualization analysis of studies on arsenic for acute promyelocytic leukemia. <i>European Journal of Integrative Medicine</i> , 2022, , 102162.	0.8	0
1269	Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 850-864.e9.	7.7	82
1270	Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?. <i>Blood Research</i> , 2022, 57, 197-206.	0.5	2
1271	A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1272	Treatment for relapsed acute promyelocytic leukemia. <i>Annals of Hematology</i> , 0, , .	0.8	5
1273	Arsenic compounds activate <sc>MAPK</sc> and inhibit Akt pathways to induce apoptosis in <sc>MA</sc> mouse Leydig tumor cells. <i>Cancer Medicine</i> , 2023, 12, 3260-3275.	1.3	2
1274	Down-regulation of hepatic cytochromes P450 1A1 and 1A2 by arsenic trioxide (ATO) in vivo and in vitro: A role of heme oxygenase 1. <i>Chemico-Biological Interactions</i> , 2022, 364, 110049.	1.7	9
1275	Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: A real-world analysis of 1105 patients over the last three decades. <i>Translational Oncology</i> , 2022, 25, 101522.	1.7	4
1276	Down-regulation of RdRp complex and activated immune response due to increased arsenic level leads to decreased corona virus replication. <i>Current Research in Microbial Sciences</i> , 2022, 3, 100162.	1.4	0
1277	Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
1278	How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy. <i>Journal of Molecular Endocrinology</i> , 2022, 69, T69-T83.	1.1	6
1279	Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging. <i>Analytical Chemistry</i> , 2022, 94, 13889-13896.	3.2	2
1280	Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	2

#	ARTICLE	IF	CITATIONS
1281	Synergistic Effects of PI3K Inhibition on Arsenic Trioxide Cytotoxicity in Acute Promyelocytic Leukemia Cells: A New Portrait of Idelalisib as an Adjuvant Therapy. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , .	0.3	0
1283	Parthenolide and arsenic trioxide co-trigger autophagy-accompanied apoptosis in hepatocellular carcinoma cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1284	An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	14
1285	Sodium arsenite and dimethylarsenic acid induces apoptosis in OC3 oral cavity cancer cells. <i>Molecular Medicine Reports</i> , 2022, 27, .	1.1	1
1286	Bioactive inorganic nanomaterials for cancer theranostics. <i>Chemical Society Reviews</i> , 2023, 52, 2031-2081.	18.7	43
1287	The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1288	Effect of arsenic trioxide on human ventricular myocytes: a model study. , 2022, , .		0
1289	Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1291	Arsenic trioxide elicits anti-tumor activity by inhibiting polarization of M2-like tumor-associated macrophages via Notch signaling pathway in lung adenocarcinoma. <i>International Immunopharmacology</i> , 2023, 117, 109899.	1.7	3
1293	Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?. <i>Clinical Drug Investigation</i> , 2023, 43, 227-239.	1.1	2
1294	Optimal combination of arsenic trioxide and copper ions to prevent autoimmunity in a murine HOCl-induced model of systemic sclerosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1301	An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	6
1310	Mechanisms of genotoxicity and proteotoxicity induced by the metalloids arsenic and antimony. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	1
1312	Pattern of bioterrorism in ancient times: lessons to be learned from the microbial and toxicological aspects. <i>Wiener Medizinische Wochenschrift</i> , 0, , .	0.5	0
1313	Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid. <i>Blood Cancer Journal</i> , 2024, 14, .	2.8	0